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DEFINITIONS

Defervescence

“Abatement of a fever as indicated by a reduction in body
temperature” (WordNet, 2011).

Endemic

“The constant presence of a disease or infectious agent within
a given geographic area or population group; may also refer to
the usual prevalence of a given disease within such an area or
group” (Last, 1988).

Epidemic

“The occurrence in a community or region of cases of an
illness with a frequency clearly in excess of normal expectancy”
(Chin, 2000).

Hyperendemic

“A disease that is constantly present at a high incidence and/or
prevalence and affects most or all age groups equally” (Last,
1988).

Outbreak

“An epidemic confined to a localized area, such as a town or
within an institutional setting like a day-care center” (Oleckno,
2002).

Pandemic

“An epidemic occurring worldwide or over a very wide area,
crossing international boundaries, and usually affecting a large
number of people” (Last, 1988).

Pantropics

“Area between the tropics of Cancer and Capricorn, defined by
the parallels of latitude approximately 23°30 ′ north and south of
the Equator” (Farlex, 2011).
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ABSTRACT

Dengue, a group of four similar viruses transmitted through the bite of a
mosquito, is estimated to infect upwards of 100 million annually in over 100
nations throughout the global equatorial belt. Distribution of global dengue is
highly skewed as Southeast Asian and Western Pacific regions endure 75% of
the global dengue burden. Similar to other regional countries, Malaysia has been
rapidly urbanizing, which has supported a hyperendemic dengue state.
The biological pathway by which dengue infection causes a wide range of
clinical manifestations, spanning asymptomatic to life-threatening severe
complications, is not comprehensively understood. Historically, severe dengue
complications have primarily occurred in children. Consequentially, the majority
of the dengue biological pathway research has been conducted on children;
however, extrapolation of research findings to adults may be inappropriate as
dengue manifestations have differed between age groups. As developing
countries undergo epidemiologic transitions and dengue continues to spread
geographically to non-endemic regions, youth and adult populations have been
subjected to more of the severe dengue burden.
Epidemiology and laboratory-based evidence has supported both memory
T-cell and antibody independent enhancement hypotheses to explain the
xii

biological pathway of severe dengue. Both hypotheses employ the central idea
that a primary infection alters immune components so that during a secondary
heterotypic dengue infection, an individual is more at risk for severe
complications.
Monocytes, immune cells that are pivotal in both hypotheses, have been
highly examined through in vivo and in vitro experimentation; however,
epidemiological evidence for monocyte involvement is incomplete. The primary
objective of the study was to examine if a difference in absolute monocyte count,
considering independent risk factors, is present in individuals with primary and
secondary dengue infections.
A secondary dengue infection was found to raise absolute monocyte count
during the defervescence phase of dengue illness in individuals aged 15 years
and older 0.71 ± 0.15 (x10^9) compared to those experiencing primary dengue
infection. Gender and distance of study participants’ residences from Hospital
Ampang were found to be risk factors for the relationship of interest; whereas,
age and race were not found to be significant risk factors.
The study helps expand current knowledge of the severe dengue
biological pathway with respect to immunological differences between primary
and secondary dengue infections. Further research is needed to confirm and
expand the findings of this initial study, specifically to include infecting dengue
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serotype, education, and socioeconomic status which are known dengue risk
factors.

xiv

INTRODUCTION
Dengue, a flaviviris transmitted by the bite of a mosquito (Aedes genus), is
currently estimated to infect upwards of 100 million individuals worldwide
annually. There are four serotypes of the dengue virus, each capable of causing
a range of manifestations from asymptomatic infection to life threatening
complications (i.e. hemorrhage, shock, severe organ impairment). Dengue is an
emerging public health threat in over 100 tropical and sub-tropical countries,
however, disproportionately burdens Southeast Asia and the Western Pacific
nations with 75% of the annual global dengue incidence (WHO/TDR, 2009; CDC,
2011).
The first recorded outbreak of dengue in Malaysia, located in Southeast
Asia, occurred in 1901 (Skae, 1902). In the last century, dengue has become
hyperendemic across much of Malaysia, meaning the disease is constantly
present at a high incidence and affects most of the population (Last, 1988). The
financial cost of dengue in Malaysia has been estimated in 2006 at US$12.8
million annually, with 54% allocated for dengue treatment and 46% towards
vector control (Suaya, Shepard, & Beatty, 2006). Even with increased vector
control efforts by the Malaysian Ministry of Health, the burden of dengue
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continues to grow as evident by the highest number of annual dengue mortality
recorded to date of 134 individuals in 2010 (MMOH, 2011).
The uncontrolled worldwide epidemics of dengue is cause for alarm;
however, until the last half century dengue was a widely unknown,
uncharacterized disease with little burden on the human population.

Global Dengue History
Due to disease similarities, the origins of the dengue virus are disputed
and are divided into two lines of thinking: African and Asian. The proponents for
the African origin point to the current commensal relationship between the
dengue virus and the primary vector Aedes aegypti, which originates from Africa.
The Asian theory of dengue origin points to recent ecological, serological and
phylogenetic evidence of Aedes aegypti and dengue virus emergence and
evolution within Asia to make their ancestral claim (Smith, 1956; Rudnick & Lim,
1986; Wang et al., 2000).
Historical documents clinically describing a dengue-like illness first appear
in China from the Chin Dynasty (265-420 Common era (CE)) (Gubler, 1998). A
gap of nearly seven centuries passes before descriptions reappear in the French
West Indies in 1635 CE (Gubler, 1997). By 1800 CE, many accounts of denguelike outbreaks along trading routes in the tropical and sub-tropical global belt had
been documented. Areas with documented dengue-like outbreaks during this
2

time period include Cuba, Brazil, Hawaii, East Africa, Syria, Egypt, United States,
Indonesia, Panama, Spain, India, Burma, and Philippines (Vasilakis & Weaver,
2008). From the early 18th to 19th centuries, dengue-like epidemics traversed the
globe including five known pandemics (Gubler, 1997). While it is impossible to
know which of the four dengue serotypes was responsible, it has been
hypothesized that only one serotype was responsible due to the lack in severe
manifestations that are currently observed to be associated with heterotypic
secondary dengue infections (Gubler, 1997).
The wave of scientific breakthroughs in infectious disease research during
the early 20th century brought empirical evidence of both the etiological agent
and vector for dengue. In 1907, U.S. Army Medical Corps Captain Ashburn and
Lieutenant Craig were stationed in the Philippines to determine if dengue was a
blood-borne disease transmitted through mosquitoes, as literature of the time
suggested (Gubler, 2004). Results of their studies were inconclusive towards the
causal vector; however, they were able to determine that the dengue agent was
in-filterable (i.e., a virus) (Gubler, 2004). Aedes egypti was demonstrated to be
the causal vector using human volunteers in 1926; followed by Aedes albopictus
in 1931 (Vasilakis & Weaver, 2008).
World War II (WWII) is a defining moment in time for dengue. Before
WWII, dengue was a little-studied disease which caused a flu-like non-fatal
illness that would typically pass within a week. The war brought many changes
which altered the environment and demographics, especially in the Asian theater
3

of war. As the Empire of Japan expanded its regional borders into southern
neighboring nations, and upon the United States of America entering the war
against Japan, tens of thousands of dengue susceptible individuals flooded into
dengue endemic regions. Mass movement of supplies and troops inadvertently
transferred dengue across much of the global tropical and sub-tropical belt
(Gubler, 1997). As a result of poorly designed urban military and civilian
developments, increased in water storage tanks, and discarded war material
serving as breeding sites for Aedes larvae dengue epidemics in Africa,
Mediterranean region, and the Americas, along with a pandemic in the Pacific
occurred throughout WWII (Gubler, 1997).
As the effect of dengue on Allied and Axis troops increased, both sides
invested resources into dengue research. Dengue virus serotype 1 (DENV-1)
was first isolated in Japan in 1943, which was quickly followed by the American
isolation of DEN-1 and dengue virus serotype 2 (DENV-2) in 1944 (Sabin, 1952).
Further investigations resulted in the development of the haemagglutination
inhibition (HI) test (Sabin, 1952). Haemagglutination inhibition allowed for a
laboratory diagnosis of dengue infection using “homotypic” immunological
responses in primary and secondary dengue infected individuals (Sabin, 1952).
These pioneering scientific discoveries permitted dengue to be distinguished
from other diseases presenting with similar clinical manifestations.
As the war concluded and troops withdrew, dengue had taken hold in the
Pacific and perceptions on the potential threat of dengue soon changed. During
4

the post-war period, displaced war refugees concentrated in already crowded
urban cities. These rapidly expanding urban centers lacked infrastructure for
sanitation and water distribution capabilities, which lead to a rise in household
water storage tanks (Gubler, 1997). Under these ideal breeding conditions
Aedes aegypti populations soared and continued to spread geographically
through military and civilian transport vehicles (Gubler, 1997). The Pacific was
now experiencing multiple co-circulating dengue serotypes contributing to the
first recorded dengue hemorrhagic fever (DHF) epidemic in Manila, Philippines in
1953 (Rigau-Perez et al., 1998). Both dengue virus serotypes 3 and 4 (DENV-3
and DENV-4) were isolated for the first time during the DHF outbreaks in the
1950s (Rigau-Perez et al., 1998). Prior to the 1953 dengue outbreak, DHF-like
symptoms had been described in two historical accounts: United States in 1780
and Greece in 1927 (Vasilakis & Weaver, 2008). Unlike the 1953 DHF
outbreaks, the historic outbreaks are thought not to have been a significant threat
to public health. Dengue fever epidemics have remained largely unobserved in
the last 25 years due to the disease endemic nature in Asia; however, DHF
epidemics have spread throughout much of the Pacific region mainly effecting
children (Pinheiro & Corber, 1997). Dengue surveillance in Malaysia
corroborates the epidemiological patterns of dengue in Asia. From 1987-1991,
dengue fever incidence continually increased from 10.4 to 32.7 per 100,000
individuals (Poovaneswari, 1993), and prior to 1982 over 50% of dengue
mortalities were in children (George & Lam, 1997).
5

Historic dengue epidemiology in the Americas is in stark contrast to that
experienced in Asia. The first record of a dengue-like outbreak occurred in
Martinique and Guadeloupe in 1635, followed by epidemics and pandemics
mirroring similar levels seen in pre-WWII Asia (WHO, 1996). However, in 1947,
in an attempt to rid Yellow Fever Virus from the Americas, an Aedes aegypti
eradication plan was implemented (WHO, 1996). Continued sero-surveillance
efforts first isolated DENV-2 in Trinidad in 1953 (WHO, 1996). By 1962, a year
before the program ended, 17 of the 47 Pan American Health Organization
(PAHO) countries had been certified as Aedes aegypti free (WHO, 1996). During
the 1960s and 1970s dengue epidemics were few in PAHO countries as a result
of the eradication program but once the program ended, countries quickly
became re-infested with Aedes aegypti. In 1999, Chile was the only country in
PAHO that remained free of Aedes aegypti (Figure 1) (Arias, 2002). In 1963,
DENV-3 was isolated and in 1968 the Americas experienced their first outbreak
of DHF in Curacao and Venezuela (WHO, 1996). With isolation of DENV-1 in
1977 and DENV-4 in 1981, the Americas, like Asia, have all four dengue
serotypes co-circulating (WHO, 1996).
As described above, the relationship between humans and dengue has
been ongoing for at least the last 17 centuries, but not until recently has the
overall interaction between species intensified due to expansion of trade, travel,
population growth, and urbanization. At present, an estimated 3 billion people
are at risk for dengue infection, of which 100 million are estimated to become
6

infected with the dengue virus annually (WHO/TDR, 2009). This level of risk will
lead to approximately 500,000 worldwide cases of DHF and 22,000 deaths
(WHO/TDR, 2009; CDC, 2011).

Figure 1. Geographic spread of Aedes aegypti in Americas before and after the
Aedes aegypti eradication program (Arias, 2002). Areas shaded in light green
indicate infestation with Aedes aegypti.

History of Dengue in Malaysia
The current relationship between Malaysia and dengue can only be fully
understood when put in a historical context. During the early 1900’s, Malaysia’s
port cities along the Strait of Malacca rapidly expanded as a result from trade
between India, China, and the European naval powers (Saw, 2007). Global
7

trade brought wealth and influence to Malaysia, but in late 1901, it also brought
the first outbreak of dengue fever to the port-city of Penang (Skae, 1902).
Following occupation during WWII, dengue outbreaks were observed throughout
the country (George, 1987). Exactly when the four different serotypes arrived in
Malaysia is unknown; however, dengue had become endemic near the time the
first outbreak of DHF was documented in 1962 (George, 1987). Today, Malaysia
is endemic for all four distinct dengue serotypes (Vinomarlini et al., 2011).
During the last half century, Malaysia’s economy has shifted from primarily
agriculture to technology- and service-based industries, which have promoted an
estimated rapid increase in urbanization from 20.4% in 1950, to 72.2% in 2010
(UN, 2009b). A rise in urban construction, litter accumulation, and poor drainage
increases the number of breeding sites for the diurnal feeding primary urban
dengue vector, Aedes aegypti (WHO/TDR, 2009). Malaysia, unlike its southern
neighbor Singapore, has experienced an increasing cyclic trend in both the
number of cases and deaths (Figure 2). The incidence rate of dengue in
Malaysia displays an increasing hyperendemic pattern, while dengue is in a
cyclic epidemic pattern in Singapore (Figure 3, A). While climates are similar in
both countries, a more comprehensive vector population control program,
especially with regard to breeding site reduction, in Singapore may aid
preventing the hyperendemic pattern of disease observed in Malaysia. Casesfatality rates have dropped below 1% in both Malaysia and Singapore
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demonstrating satisfactory rehydration treatment of dengue patients (Figure 3, B)
(WHO/WPR, 2011).

Figure 2. Number of total cases (A) and deaths (B) in Malaysia (black) and
Singapore (gray) from 2000 to 2010 (WHO/WPR, 2011).

In a retrospective cross-sectional study from 1998 to 2003, Hussin and
colleagues (2005) reported a 1.23 male/female ratio in hospitalized symptomatic
dengue infections in Kota Bharu, Malaysia. The pattern of higher rates of
reported symptomatic infection in males has been observed in other Southeast
Asia Region (SEAR) dengue studies (Yew et al., 2009). Why male hospitalized
dengue infections are reported more frequently than female has yet to be fully
understood. Potential risk factors for future investigation include increased
outdoor activity by males, leading to increased vector exposure, and females
9

having more coverage of their body with clothing as dictated by religious beliefs,
leading to decreased vector exposure.
Studies have observed a protective effect amongst Africans and
individuals with African decent (Halstead et al., 2001; Sierra, Kouri, & Guzman,
2007). Researchers have hypothesized genetic polymorphisms within this
population maybe the contributing protective factor (Kyle & Harris, 2008).
Research on Human Leukocyte Antigen (HLA), a region on human chromosome
six that contains immune system genes, may play a major role in development of
severe disease. Recent research on Malaysian populations has identified
several HLA types to be risk factors for development of severe dengue
complications (Appanna, Ponnampalavanar, Lum Chai See, & Sekaran, 2010).
The Malaysian population consists of 90% Malay, Chinese and Indian; the
remaining 10% is mainly individuals from other SEAR countries and individuals of
European descent with very few individuals with African ancestry (J. Sathar,
personal communication, March 2011).
In World Health Organization (WHO) SEAR and Western Pacific Region
(WPR) member states, children (<15 years) have historically borne the majority
of adverse outcomes, in quantity and severity, associated with dengue infection
(WHO/TDR, 2009). Research has suggested this maybe in part due to increased
capillary fragility among children (Gamble et al., 2000). From 1973, when
dengue became a reportable disease in Malaysia, until 1981, the pattern of
elevated mortality among children compared to adults persisted. George and
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Lam (1997) reported that since 1982 over 50% of dengue related mortality was
observed among individuals over the age of 15 in Malaysia. The increased
pattern of dengue mortality in adults has also been observed in Thailand and is
even more pronounced in Singapore (Cummings et al., 2009). From 2004 to
2008, 24 of the 28 adults who died of dengue in Singapore were older than 45
years of age (Chua, 2010).

Figure 3. Incidence rate (per 100,000 population) (A) and case-fatality rate (per
100 DF/DHF cases) (B) in Malaysia (black) and Singapore (gray) (WHO/WPR,
2011).

No study to date has undertaken why the average age of dengue mortality
has been increasing in Malaysia, but studies have attempted this in other SEAR
nations. These studies have suggested the contributing factors to be urban
11

development, vector control practices, distribution changes in viral serotype and
genotypes, change in age distribution, increased immigration and migration
patterns, and increasing life expectancy with concurrent decreasing birth rate
(Nagao, & Koelle, 2008; Halstead, 1994; Wichmann et al., 2004; Reves, 1985;
Cummings et al., 2009). Together these factors may decrease the dengue
susceptible population, which reduces the rate that dengue susceptible
individuals contract the disease (known as force of infection) (Cummings et al.,
2009). Consequently, more individuals will contract a secondary heterotypic
dengue infection later in life.
Comparing to the above studies’ findings, Malaysia already displays many
of the contributing trends that may reduce the force of dengue infection.
Sustained socioeconomic improvements and a vector control program may
decrease the number of people at risk of exposure. Population structural
changes also continue to contribute. Since 1970, Malaysia’s crude death rate
and crude birth rate have been declining, whereas, life expectancy has been
increasing (Figure 4) (UNICEF, 2011). These factors will lead to an overall
increased median age of the Malaysian population (Figure 5) (UNICEF, 2011),
along with increasing the number of non-susceptible dengue individuals further
reducing the force of the infection. Additional changes to the Malaysian
population structure come as a result of adult immigration from surrounding
countries and migration from rural Malaysia where the incidence rate of dengue
may not be as high.
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The above factors may combine to create longer intervals between
dengue infections within the Malaysian population, resulting in a greater
proportion of individuals acquiring a secondary infection during adulthood.
Observations from Cuba have suggested that increased time between dengue
infections increases the risk for severe dengue complications (Guzman et al.,
2002).

Figure 4. Malaysian crude death rate (per 1000), crude birth rate (per 1000) and
life expectancy in 1970, 1990 and 2009 (UNICEF, 2011).

Hypotheses for the biological pathway by which severe dengue
complications manifest, include antibody dependent enhancement and
reactivation of memory T-cell. Both hypotheses incorporate the notion that a
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primary dengue infection alters the immune system, whereby severe
complications arise during a secondary heterotypic dengue infection. Integral in
the mechanics of both hypotheses are various immune cells such as monocytes,
dendritic cells, and T-cells (Halstead, 1994).

Figure 5. Age-sex structure in Malaysia, 2000 & 2050 (UN, 2009a).

As more countries within Asia, Africa, and Americas enter the second and
third phase of Omran’s (1971) epidemiological transitions, populations will
continue to age, increasing the severe dengue burden upon adults (See
Appendix A for discussion of epidemiological transitions). Epidemiological
studies in Malaysia to date have described adult dengue manifestations, tried to
determine the differences in symptomatic dengue manifestations between adults
14

and children, and identified potential serum markers in adults as potential
biomarkers for early identification of severe dengue cases (Lum, Suaya, Tan,
Sah, & Shepard, 2008; Tee et al., 2009; Thayan et al., 2009). Historically,
dengue studies have concentrated on the determinants and biological pathways
of severe dengue development within the population aged less than 15 years.
With the ongoing shift in burden of severe dengue mortality to individuals above
15 years of age, there is an immediate need to expand investigations on the
biological pathway of severe dengue in those above 15 years of age, especially
within WHO SEAR & WPR member states.

Statement of the Problem
Estimated to infect upwards of 100 million annually in over 100 nations
throughout the pantropics, the equatorial region between the tropic of Cancer
and Capricorn, dengue, within the last half century, has emerged as the principal
arthropod-borne virus (arbovirus) public health threat. Distribution of global
dengue is highly skewed as Southeast Asian and Western Pacific regions endure
75% of the global dengue burden.
Similar to other regional countries, Malaysia has been rapidly urbanizing
which has supported a hyperendemic dengue state. A low death rate and high,
yet decreasing birth rate has increased the Malaysian population size, median
age, and life expectancy. The ongoing epidemiological transition in Malaysia has
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potentially raised dengue herd immunity. Consequently, this increases time
between dengue infections, which is a risk factor for development of severe
dengue, and age at which individuals experience a secondary heterotypic
dengue infection. Research has primarily examined severe dengue in children,
and extrapolation of findings to adults may only be partial as dengue
manifestations have differed between age groups.
The severe dengue biological pathway is not comprehensively
understood, although epidemiology and laboratory-based evidence has
supported both memory T-cell and antibody independent enhancement
hypotheses. Monocytes, pivotal in both hypotheses, have been highly examined
through in vivo and in vitro experimentation (Ubol & Halstead, 2010); however,
epidemiological evidence for monocyte involvement is incomplete. Previous
dengue infection, determined by the hemagglutinin inhibition assay, is a principal
severe dengue risk factor, however, epidemiological assessment of previous
dengue infection status with venous absolute monocyte count is lacking.
Uncontrolled capillary effusion, the loss of bodily fluid potentially leading to
shock, is the primary cause of mortality from dengue. Monocytes have been
indicated as a possible predictor of severe dengue (Potts et al., 2010), although
further epidemiological examination is needed to confirm the association taking
into consideration independent risk factors.
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Significance of the Study
The study is a subset of a data from a larger cross-sectional study that
was conducted in a previously un-described dengue population. Dengue
manifestations have shown to differ between populations. Description of clinical
manifestations during dengue disease of the study population will allow for
comparison to the dengue literature. Also, the descriptive undertaking remains
important as the current dengue classification criteria was recently updated and
there is still a need to ensure the criteria can be effectively used on all global
dengue populations.
The study attempted to clarify through epidemiological methods the
relationship of venous absolute monocyte count with primary and secondary
dengue infection status, taking into consideration the effects of independent risk
factors, during the defervescence phase of illness. Monocytes are of particular
importance due to their in vitro and in vivo empirically determined involvement in
both innate and adaptive dengue immunity. Among dengue patients, monocytes
have been previously observed to decrease in venous blood samples during
defervescence. As a previous dengue infection has been observed to be a
significant risk factor for severe dengue complications during a heterotypic
secondary dengue infection, determining if previous dengue infection status
alters immunological responses, specifically venous absolute monocyte count, is
of significant interest in elucidating the severe dengue biological pathway.
Understanding how independent risk factors affect the relationship between
17

primary and secondary dengue infection and monocyte level, may provide
currently absent epidemiological support and clarity on the antibody dependent
enhancement and/or reactivation of memory T-cell severe dengue hypotheses.
Additional epidemiological assessment of the association between
monocytes and the outcome of vascular leakage/hemorrhage, while considering
independent risk factors, may provide further insights into the severe dengue
biological pathway with respect to monocyte involvement.

Purpose of the Study
The primary purpose of this cross-sectional study was to collect data and
analyze the association of venous absolute monocyte count with primary and
secondary dengue infection status during defervescence considering the role of
independent risk factors (e.g. gender, age, race, and distance from patient
residence to hospital) among hospital admitted dengue patients above 15 years
of age in Federal Hospital Ampang, Selangor, Malaysia from June to December
2010.
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Aims of the Study
Primary aims of the study include:
1) Describe the demographics, co-morbidities, manifestations, and
laboratory results of the study population by primary & secondary
dengue infection status and absence & presence of
hemorrhage/vascular leakage.
2) Determine the relationship of venous absolute monocyte count with
primary and secondary infection considering the effects of the
independent risk factors gender, age, race, and distance of
residence from hospital, during defervescence.
Secondary aims of the study include:
1) Determine the relationship of venous absolute monocyte count with
presence and absence of hemorrhage/vascular leakage, considering
the effects of the independent risk factors gender, age, race, and
distance of residence from hospital, during defervescence.
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LITERATURE REVIEW
A literature review was performed using the following searchable
published literature databases: PubMed, Web of Knowledge and Science Direct.
The searches used the keywords: dengue, monocyte, macrophage, secondary
infection, hemorrhage, and vascular leakage. Results were limited to English
written articles and were extracted by March 25th, 2011.

The Unknown Severe Dengue Biological Pathway
A literature review on the development of severe dengue reveals multiple
hypotheses all of which have biological plausibility (Rodenhuis-Zybert, Wilschut,
& Smit, 2010). The elusiveness of conclusive empirical evidence pointing toward
a single hypothesis has prompted experts to suggest that the ultimate causal
pathway for the development of severe dengue complications is most likely
multifactorial (Whitehorn & Farrar, 2010). Central hypotheses for the
development of severe dengue include: viral virulence, reactivation of memory
T-cells, HLA type, and antibody-dependent enhancement (ADE) (Kyle & Harris,
2008). As the study is epidemiological in nature, the intended purpose of the
below section is to not present a comprehensive review of the microbiology of
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dengue pathogenesis; dengue pathogenesis reviews may be found elsewhere
(Ubol & Halstead, 2010; Rothman, 2010; Kyle & Harris, 2008). The intended
purpose is to introduce a generalized platform of knowledge which allows for
understanding of the current literature gap and interpretation of study results.
The hypothesis of viral virulence revolves around the central idea that a
particular serotype or genotype of dengue virus is inherently more prone to cause
severe dengue complications (Whitehorn & Farrar, 2010). In 1997, an outbreak
of DENV-2 was detected in Cuba which produced high incidence rates of severe
dengue manifestations (Guzman, Kouri, & Halstead, 2000). Genotyping of the
1997 Cuban virus indicated mutations had occurred compared to a similar yet
less severe Jamaican DENV-2 strain (Guzman et al., 2000). Under the viral
virulence hypothesis, a mutation in the 1997 Cuban DENV-2 strain increased the
virulence of the virus. The viral virulence hypothesis alone does not support
observed epidemiological evidence as many people will be infected with dengue
during an epidemic, however, only a fraction of cases will develop severe
complications (Martina, Koraka, &Osterhaus, 1999).
Intrinsic risk factors, especially the involvement of the host immune
response, provide a more promising explanation for why only a small proportion
of dengue infected individuals develop severe dengue complications. As
previously explained, studies have identified associations between HLA type and
dengue disease severity (Appanna et al., 2010). Further research on HLA types
have the potential to add knowledge to the pathogenesis theories of dengue, and
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can also be used as a tool to identify individuals at an increased risk for dengue
disease (Kyle & Harris, 2008). Larger studies are needed to confirm and expand
initial findings.
The reactivation of memory T-cells and ADE hypotheses are both based
on the notion that following a primary infection, the host immune system is
altered or primed such that upon a secondary infection, a severe immunological
reaction occurs (Pang, Cardosa, & Guzman, 2007). Central to both hypotheses
are the involvement of monocytes. Produced from progenitor cells in the bone
marrow and stored in the spleen, monocytes are the parent cells found naturally
in the circulatory system that undergo differentiation and activation into
macrophages and dendritic cells once they enter tissues (Imhof & Aurrand-Lions,
2004) (Figure 6).
Antibody dependent enhancement in dengue is supported by the
epidemiologic findings of increased risk during a secondary heterotypic dengue
infection (Ubol & Halstead, 2010). During a primary dengue infection the
adaptive immunity pathway is activated and B-cells produce antibodies specific
against the infecting serotype. However, antibodies which are cross-reactive
with the other dengue serotypes are also produced (Pang et al., 2007). The
cross-reactive antibodies provide a transient period of time that the individual is
immune to all dengue serotypes. After roughly three months the cross-reactive
antibodies are no longer maintained at levels capable of providing complete
dengue protection (Dengue Virus Net, 2011). The primary dengue infection has
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altered the immune system in that cross-reactive antibodies are present, but at
non-neutralizing levels (Kyle & Harris, 2008).
During a heterotypic secondary dengue infection, cross-reactive
immunoglobulins from a primary dengue infection bind to the virus of the
secondary infection. As cross reactive antibodies have dropped below
neutralizing levels, inactivation of the dengue virus is not achieved. Instead, the
dengue virus and cross-reactive antibody attach to macrophages/monocytes via
their Fc-receptor (Pang et al., 2007). Dengue virus has been shown to be
capable of infecting dendritic cells, monocytes, macrophages, lymphocytes,
hepatocytes and vascular endothelial cells (Leong, Wong, Leong, Tan, &
Wannakrairot, 2007). Replication of dengue virus has been observed in dendritic
cells, but primarily occurs in monocytes & macrophages (Rodenhuis-Zybert et al.,
2010).
Halstead and colleagues (2010) have suggested an intrinsic ADE model in
which binding via the Fc-receptor on a monocytic cell of a cross-reactive antibody
and dengue virus enhances dengue viral replication within the monocytic cell
followed by proinflammatory cytokine output (Halstead, Mahalingam, Marovich,
Ubol, & Mosser, 2010) (Figure 7). The intrinsic ADE model is supported by
epidemiological evidence in which high levels of viremia and proinflammatory
cytokines are associated with increased risk of severe dengue complications
(Kyle & Harris, 2008; Pang et al., 2007; Avirutnan et al., 2006; Endy et al., 2004;
Libraty et al., 2002). The ADE hypothesis can also explain the appearance of
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severe dengue in infants. Pengsaa and colleagues (2003) reported that
maternally transferred dengue neutralizing antibodies were detectable at
decreasing levels in infants until nine months after birth. Under the ADE
hypothesis, an infant with a primary dengue infection and non-neutralizing levels
of maternal anti-dengue antibodies would be at increased risk for developing
severe dengue complications.

Figure 6. “Origin and haematopoietic differentiation of myeloid antigenpresenting cells” (Imhof & Aurrand-Lions, 2004).

The ADE hypothesis is supported by the epidemiological finding that
secondary dengue infection is a risk factor for development of severe dengue;
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however, key holes in the dengue ADE literature fail to explain all epidemiological
evidence. Severe dengue complications have been observed to manifest during
the defervescence phase of dengue illness, which approximately occurs on day
five of symptomatic illness (WHO/TDR, 2009). ADE incorporates innate
immunity, which has a rapid response time to infection. As currently presented,
dengue ADE does not explain the epidemiological evidence of delayed
manifestations of severe dengue complications as viremia levels have been
observed to decrease significantly by the onset of defervescence (WHO/TDR,
2009).
Under the reactivation of memory T-cells hypothesis, during a primary
dengue infection the virus is phagocytized by macrophages/monocytes and viral
antigens are presented on the cell membrane to activate memory T-cell
production (Pang et al., 2007). As the four dengue serotypes have 60-70%
homology, cross-reactive memory T-cells will potentially be produced (Wong et
al., 2007). During a secondary heterotypic dengue infection, the virus will again
be phagocytized by macrophages/monocytes and viral antigens displayed on the
surface. Cross-reactive memory T-cells produced during the primary infection
recognize the viral antigens displayed by macrophages/monocytes during the
secondary heterotypic dengue infection, which results in the activation of the
memory T-cell and release of cytokines (Beaumier, Mathew, Bashyam, &
Rothman, 2008). Memory T-cell released cytokines have been observed to
attract immunologic cells, such as: macrophages, monocytes and memory T25

cells to the site of infection, subsequently increasing the level of cytokine release
(King, Anderson, & Marshall, 2002).

Figure 7. “Intrinsic antibody-dependent enhancement of dengue virus infection in
THP-1 human monocytic cells.” ADE=antibody-dependent enhancement.
Th2=Thelper 2. DENV=dengue virus (Halstead et al., 2010).

Raised levels of activation and proliferation of memory T-cells in dengue
infection has been associated with increased risk for severe dengue
complications (Rothman, 2010). Among the cytokines released by the memory
T-cells are proinflammatory cytokines (i.e. interferon gamma & tumor necrosis
factor alpha) (Pang et al., 2007; Rothman & Ennis, 1999). Elevated levels of
proinflammatory cytokines have been associated with increased vascular
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permeability during dengue infection (Mongkolsapaya et al., 2006). Vascular
leakage is the primary mechanism for dengue infection resulting in mortality
(Avirutnan et al., 2006). As memory T-cell attraction and activation at the site of
infection is a slower immunological process than the innate immune response
hypothesized in ADE, the reactivation of memory T-cells hypothesis can better
explain the epidemiological observation of delayed severe dengue complication
manifestation (Nielsen, 2009).
While heavily investigated with in vitro and in vivo studies due to their role
in both ADE and memory T-cell hypotheses, monocytes have remained poorly
examined under epidemiological studies. A literature review on
monocytes/macrophages investigated under epidemiological studies has
revealed the following. In children (<15 years of age), clinical epidemiological
studies have observed significantly lower absolute monocytes counts in dengue
patients compared to other febrile illnesses (Kalayanarooj et al., 1997; Green et
al., 1999). Monocyte activation has been associated with severe dengue
manifestations (Durbin et al., 2008). Potts and colleagues (2010) have used
classification and regression tree analysis to identify in Thai pediatric patients
clinical laboratory predictor models for severe dengue. Their results found that a
percent monocyte cut-off of ≤ 9%, along with other variables, was capable of
identifying patients with dengue shock syndrome (Potts et al., 2010). An
epidemiological study in adults found an association by dengue serotype of
higher monocyte count in DENV-2 compared to DENV-1 (Tsai et al., 2009).
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The literature review undertaken did not return an epidemiological study
which investigated the relationship of venous absolute monocyte count with
primary and secondary dengue infection status or relationship of venous absolute
monocytes with absence or presence of hemorrhage/vascular leakage.
Therefore, the study described here attempts to fill the literature gap of absolute
monocyte count in primary versus secondary dengue infection during the
defervescence phase of illness. The study also attempts to assess the use of
absolute monocyte count as an indicator of severe manifestations using novel
outcome criteria.

The Epidemiological Triad
The epidemiological triad is a traditional model for infectious disease
causation comprised of the components external agent, susceptible host, and an
environment, which brings the agent and host in contact. To model the complex
relationships found in vector-borne diseases, the traditional infectious disease
epidemiological triad has been supplemented to include a centralized vector
component (Chadee, Williams, & Kitron, 2005). The transmission cycle of an
infectious disease can be interrupted with reduction or removal of a single model
component; however, the presence of all model components in sufficient
quantities can result in epidemics.
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During the past 60 years, global components of the dengue
epidemiological triad have all dramatically increased resulting in a significant rise
in dengue incidence worldwide (Guha-Sapir & Schimmer, 2005) (Figure 8). In
the following section, the dengue epidemiological triad of disease causation is
discussed by each contributing factor providing a background on the changing
interactions.

Figure 8. Dengue epidemiologic triad of disease causation (PSU, 2010) edited.
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Agent
Dengue virus is a member of the large pathogenic virus family Flaviviridae
that includes more than 70 other medically important tropical diseases, including
yellow fever, Japanese encephalitis, hepatitis C, and West Nile virus (Lupi, 2011)
(Figure 9). Within the virus genus Flavivirus, dengue virus is the culpable agent
responsible for the highest human case-fatality rate (Qi, Zhang, & Chi, 2008).
The mapped 11kb genome of the enveloped positive single stranded RNA
dengue virus encodes for a viral particle composed of three structural and seven
nonstructural proteins (Perera, & Khun, 2008). There are four serologically
similar dengue viruses (DENV-1, -2, -3, and -4) each with three to five genetic
groups (genotypes). Each serotype of dengue is genetically and anti-genetically
diverse (Perera, & Khun, 2008).

Vector
Dengue is transmitted by the mosquito-vectors Aedes aegypti and Aedes
albopictus. Unlike the malaria vectors of the genus Anopheles, the dengue
vectors are active during daylight hours with peak feeding activities occurring
during at dawn and dusk (Jansen & Beebe, 2009). Adult Aedes females favor
human blood meals and are capable of biting multiple hosts in a single
gonotrophic cycle (Jansen & Beebe, 2009). Preferred breeding sites of Ae.
albopictus are small natural or man-made stagnant fresh water containers in rural
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or peri-urban areas (Paupy, Delatte, Bagny, Corbel, & Fontenille, 2009). On the
other hand, Ae. aegypti is found primarily in fast growing urban settings that allow
for innumerable man-made breeding locations (Jansen & Beebe, 2009). Aedes
aegypti is an adaptive vector fully capable of sustaining a reproducing population
within human dwellings (Jansen & Beebe, 2009).

Figure 9. “Flaviviridae phylogenetic tree (unrooted)” (UTMB, 2009) edited.

31

Life Cycle
The Aedes vectors have a four stage lifecycle: egg, larvae, pupae, and
adult (Figure 10). The eggs of Aedes are highly durable surviving in desiccated
states for over a year and remaining viable after wintering in frozen water. Eggs
must be laid in fresh water and hatch within 2-7 days when temperatures are
greater than 12°C. The development and survival of larvae is dependent on
environmental conditions, including temperature, humidity, predation, and water
depth (>10mm). Larvae pupate after a minimum of 4 days after reaching a
minimum weight. The pupae stage lasts for 2 days in temperatures greater than
18°C from which the adult mosquito emerges. The avera ge lifespan of an adult
Aedes is two weeks (CDC, 2011; Jansen & Beebe, 2009).

Figure 10. Lifecycle of Aedes aegypti & Aedes albopictus (CDC, 2011).
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Natural History
The dengue virus lifecycle is human-mosquito-human. Dengue is also
transmitted in a non-human primate-mosquito-non-human primate lifecycle (Kyle
& Harris, 2008). These sylvatic cycles have been demonstrated in both Asia and
Africa (Gubler, 1998).
The adult female Aedes mosquito, after taking a blood meal on a dengue
viraemic host, has an extrinsic viral incubation period of 8-10 days. The extrinsic
incubation period refers to the time it takes for the dengue virus to replicate in the
abdomen and disseminate into the mosquito’s salivary glands (Salazar,
Richardson, Sánchez-Vargas, Olson, & Beaty, 2007). During feeding, the
mosquito injects saliva into the host that contains proteins to interrupt the host
clotting cascade to allow the mosquito to take a blood meal. The mosquito will
remain infectious for the remainder of the normal one to two week Aedes
lifespan, even after multiple feedings. The human intrinsic incubation period
lasts for 3-14 days, with an average of 4-7 days, after which viremia levels are
elevated enough that a mosquito taking a blood meal can acquire the dengue
virus (CDC, 2011). Vertical transmission of dengue within vectors has been
demonstrated (Thenmozhi et al., 2007).
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Environment
Climate
The dengue vector lifecycle (adult survival, reproduction rate, and egg,
larvae, and pupae development) is highly influenced by climatic factors, including
temperature, precipitation, and humidity. Tropical conditions with high
temperature, humidity levels, and precipitation are ideal conditions that promote
elevated mosquito populations and rapid extrinsic incubation periods. A
shortened extrinsic period increases the risk for dengue infection to the human
population as adult mosquitoes will be infectious for a longer duration of their
lifespan (CDC, 2011).
Due the reproductive nature of the dengue vectors, a cyclical pattern in
dengue disease is observed in response to the monsoon season. During the
monsoons, breeding sites, both natural and man-made, become more abundant
allowing for a spike in the mosquito population, subsequently increasing the risk
for dengue infection. This cyclic pattern of peaking dengue cases during the
summer monsoon months can be observed in Figure 11, depicting the number of
reported dengue cases in Thailand per month from 1990-2007. Dengue vectors’
inherent propensity to thrive under tropical climatic conditions has concentrated
the risk of dengue around the global equatorial belt; however, historic dengue
surveillance has observed the worldwide distribution of dengue to not simply
follow climatic conditions.
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Figure 11. Thailand: Seasonal trend of dengue cases (1990-2007 April)
(WHO/SEAR, 2011).

Surveillance
Dengue surveillance is an extremely beneficial practice that has
elucidated temporal and spatial trends on global, regional, and local levels.
Understanding the general trend of dengue over time has been achieved by
graphing the total number of cases with dengue and countries reporting dengue
cases to WHO from 1955 to 2005 (Figure 12) (WHO/TDR, 2007). The number of
countries reporting dengue cases jumped in the early 1960s, followed by a
plateau until the early 1980s. Since the early 1980s, countries reporting dengue
cases have been gradually increasing. The total number of cases did not begin
to rise significantly until the late 1970s. A cyclic increasing trend is noticeable in
the number of countries reporting dengue cases and the total number of cases
reported; however, their patterns do not mirror each other. A definitive answer
for why dengue total cases fluctuate with year is complex and geographically35

specific, as there are many contributing factors (see Extrinsic Risk Factors) (Kyle
& Harris, 2008).
To investigate the trend of dengue at the country level, the incidence rates
of reported dengue fever (DF)/DHF per 100,000 in selected WHO SEAR member
states was graphed (Figure 13). Each member state presents a cyclical pattern
in their incidence rate, though the rate of that pattern varies within each state and
between states. Variation within dengue surveillance among geographically
close countries allows for the inference that risk factors that operate within
countries heavily influence the incidence rate of dengue.

Figure 12. Dengue cases: Global annual number of cases reported and number
of countries reporting to WHO by year, 1955 to 2005 (WHO/TDR, 2007).
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Serotype-surveillance of dengue infections allowed for the discovery that
typically only one or two serotypes are predominant for a period of one-three
years (Figure 14) (Adams, et al., 2006). This information has permitted insight
on how dengue can maintain high incidence overtime. A population experiencing
high transmission of a serotype(s) for a period of time will result in a decrease of
overall susceptibility within the effected population to that serotype(s). The drop
in transmission of the dominant serotype(s) will allow a different serotype, which
has higher levels of susceptibility in the population, to emerge. This relationship
permits the serotypes to change, but will keep the incidence rate at elevated
levels.

Figure 13. Incidence rates of reported dengue fever & dengue hemorrhagic
fever per 100,000 in selected World Health Organization Southeast Asia Region
member states (WHO/SEAR, 2011).
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Total DHF cases reported to WHO have been graphed by year for both
the Americas and Asia (Figures 15 & 16) (Arias, 2002). Both regions display an
increasing cyclic trend, although the Americas have fewer overall reported DHF
cases. As previously discussed, the lag time in the appearance of DHF in the
Americas was primarily due to the Aedes aegypti eradication program run from
1947 to 1963. Overlaying the total reported DHF cases of the Americas and Asia
by year starting for each at the first recorded observance of DHF presents a
striking similar pattern (Figure 17) (Arias, 2002). If risk factors of dengue
continue to exacerbate the situation in the Americas, one can make an inference
that DHF may approach that currently observed in Asia, after controlling for
population differences.

Figure 14. “Monthly confirmed cases of dengue by serotype at Queen Sirikit
National Institute of Child Health, Bangkok 1980 to 2000” Red, DENV-1; blue,
DENV-2; green, DENV-3; black, DENV-4 (Adams, et al., 2006).
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Figure 15. Total reported cases of dengue hemorrhagic fever in the Americas by
year from 1981-2001 (Arias, 2002).

Figure 16. Total reported cases of dengue hemorrhagic fever in the Asia by year
from 1955-1999 (Arias, 2002).
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Figure 17. Total reported cases of dengue hemorrhagic fever in the Asia and
Americas by year matched by first year of appearance (Arias, 2002).

Plotting the dengue case fatality percent for DHF of the member states of
the WHO Southeast Asia region by year from 1985 to 2006 demonstrates a clear
cyclic decreasing trend (Figure 18) (WHO/SEAR, 2011). The cyclic trend might
be influenced by many risk factors, including viral strain, intrinsic factor (i.e.,
genetics), susceptible population, prevention practices, and climate factors.
Reasons as to why some years see greater case fatality among DHF patients
has yet to be fully deduced. The overall decreasing trend observed in the case
fatality percent since 1985, may in part be due to greater awareness of the
disease among medical personnel and proper management of rehydration
therapy. Under proper medical care, DHF patients typically experience a case
fatality rate of around 1% throughout the world (Kyle, & Harris, 2008). Although
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with absent or improper care, case fatality rates have been observed in DHF
patients as high as 20% (Monath, 2007).

Figure 18. Case fatality rate of countries within the World Health Organization
Southeast Asia region (WHO/SEAR, 2011).

Extrinsic Risk Factors
Extrinsic risk factors for dengue are associated with the environment, and
influence the amount of risk for acquiring a dengue virus infection at a particular
location. Recognized extrinsic risk factors for dengue include endemic dengue
vector population, mass transportation, water access, urbanization, population
growth, waste accumulation, dengue susceptibility of the population, climate,
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circulating dengue viral strain, housing type, population density, and preventative
measures implemented in the community (Gubler, 1997).
World Health Organization marks the 10°C July and Janua ry isotherms as
the year-round boundary of risk for dengue infection (Figure 19) (WHO, 2010).
Concerns have been raised as to whether global warming will contribute to the
geographic spread of dengue risk. Researchers have modeled the hypothetical
increase in risk from dengue with global temperature rise (Figure 20) (Hales, de
Wet, Maindonald, & Woodward, 2002).
Jansen and Beebe (2010) argue that global models based solely on
climatic factors do not accurately model increased risk for dengue. They present
the example of southern Australia where climatic shifts have reduced rainfall
totals significantly below historical levels. A climatic model would indicate the
region to be undergoing a reduction in risk for dengue, but the authors point the
human element. As southern Australia dries, the government and private
citizens have created more water retention structures (i.e. dams, cattle troughs,
rain barrels, etc.). Aedes is highly adapted to human environmental intervention
which in southern Australia may lead to an overall increased dengue risk if
proper preventative steps to reduce breeding sites are not taken.
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Figure 19. Countries reporting dengue in 2010 (WHO, 2010).

The extrinsic risk factors that have and continue to hold the most potential
for influencing the epidemiology of dengue are mass transportation, population
growth, and urbanization. The last half century has seen drastic changes in the
global distribution of the dengue vectors (Guzman & Istúriz, 2010). Mosquitoes
have very limited self dispersion capabilities (Russell, Webb, Williams, & Richie
2005), making the vast geographic spread of the dengue vectors attributed to
increased international commerce and mass mobilization of the human
population (Kyle & Harris, 2008). In 2006, an estimated 2.1 billion individuals
around the world boarded a plane (Mangill & Gendreau, 2005), while last year,
there were 935 million international tourists (WTO, 2011). As the human
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population continues to grow in mobility, so do the chances that an infectious
disease will breakout into a new geographic location (Armelagos, 1998).

Figure 20. “Estimated baseline population at risk in 1990 (A) and estimated
population at risk in 2085 (B)” Range: Dark Blue 0.0-0.1 to Red 0.9-1.0 (Hales et
al, 2002).

Since peaking in the mid-1960s, global population growth rates have been
steadily declining (Figure 21); however, the small decreases in growth rate are
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not enough to decrease the overall global population within the next 40 years
(Figure 22) (US Census Bureau, 2011). Continued growth of the world
population will raise the risk for dengue infection as there will be more
opportunities for transmission with dengue susceptible individuals.

Figure 21. World population growth rate: 1950-2050 (US Census Bureau, 2011).

Urbanization is a significant extrinsic risk factor for dengue infection (Kyle,
& Harris, 2008). The minimum population necessary to sustain dengue
transmission is estimated between 10,000 to 1,000,000 individuals (Gubler,
1997). In these populations, there are enough dengue susceptible individuals
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that come in contact with the infected vectors to allow for continued disease
transmission. In less developed nations, population growth may outstrip
infrastructure for proper housing, sanitation, and potable water. As a result,
increase fresh water filled containers in and around human residences may
occur. These ideal breeding sites for dengue vectors will allow for greater vector
populations within urban environments (Kyle, & Harris, 2008).

Figure 22. “World Population: 1950-2050” (US Census Bureau, 2011).
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The presence of multiple co-circulating dengue serotypes is a significant risk
factor for the development of severe dengue. Geographic distribution of dengue
serotypes is uneven and should be taken into consideration during severe
dengue predictive modeling. Fried and colleagues (2010) found no statistically
significant difference in development of dengue hemorrhagic fever by serotype.
The relationship between the dengue and the environment is highly
complex and cannot be modeled globally solely using climatic indicators. With
proper consideration to all extrinsic risk factors including “urbanization,
socioeconomic factors, building design, water supply and management, and
public health services,” Jansen and Beebe (2010, p.274) suggest that accurate
modeling maybe possible at the local and regional levels.

Global Burden of Dengue
Currently, dengue has a global reach including developed and less
developed nations; however, the burden of dengue is geographically highly
stratified. Today, the WHO SEAR and WPR contain 75% of the global of the
global dengue burden (WHO/SEAR, 2011). In the WPR, 25 of 37 states and
territories reported dengue cases; whereas the Democratic Peoples Republic of
Korea was the only SEAR dengue member state not reporting native
transmission of dengue (WHO/SEAR, 2011; WHO/WPR, 2011).
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Population growth and urbanization are risk factors that can increase the
burden of dengue. Population levels of more developed nations, both in urban
and rural areas have and will continue to remain relatively constant; whereas less
developed rural population levels are predicted to begin falling within the next
decade. Urban areas within developing nations are expected to have a
continued significant increase during the coming decades (Figure 23) (UN,
2009a). Population growth of these less developed nations in urban settings is
primarily a result of natural population growth, although migration within the
country from rural settings and immigration from other countries contributes to
urbanization (UN, 2010).
The effect of urbanization has an entirely different set of outcomes
depending on whether it occurs in a more or less developed nation. Developed
nations have relatively strong economy which permits the government ample
resources to invest in water, drainage, and sanitation infrastructure. These
investments have allowed for a transition from primarily infectious diseases
mortality within the state to chronic disease. Many less developed nations do not
possess the resources for infrastructure expansion to keep pace within the
rapidly expanding cities. The urban poor are disproportionately affected by
infectious diseases as a result of disparities in healthcare, increased contact risk,
and increased mobility within urban environments (Alirol, Getaz, Stoll, Chappuis,
& Loutan, 2010).
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Figure 23. Historic and predicted global population growth by development and
rural/urban status (UN, 2009a).

Prevention
Without a licensed dengue vaccine, control and prevention of dengue has
focused on vector eradication programs. Vector control programs that have seen
limited success focus on sustained local efforts to eliminate breeding sites and
not large scale infrequent responses, such as communitywide fumigation
(Ballenger-Browning & Elder, 2009). Modern societies produce large quantities
of disposable non-biodegradable containers which accumulate and retain
rainwater. Urban residences also have many containers which retain stagnant
water ideal for breeding including potted plants, gutters, water storage, and air
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conditioners (Kyle, & Harris, 2008). Health department education programs and
public service announcements continue to attempt to educate and organize the
public to eradicate dengue breeding sites; however, until a widespread
behavioral change occurs in the majority of a population, dengue will continue to
a public health threat.

Host
Pathophysiology
Dengue virus infection can cause a range of manifestations from
asymptomatic infection to life threatening shock, hemorrhage, and organ failure
(WHO/TDR, 2009). Of the100 million annually estimated dengue infections, 1050% will develop a symptomatic response. Only a small percentage of the
individuals who develop symptomatic dengue infections will be captured by
surveillance systems and/or develop severe complications (Figure 24) (Kyle, &
Harris, 2008). There is currently no way to determine how an individual will
respond after being infected with dengue virus (Kyle, & Harris, 2008).
Following infection from a dengue infected vector, an individual will
experience a four to ten day incubation period (WHO/TDR, 2009). Viremia levels
reach detectable and transmittable levels approximately one day before
manifestation of overt symptoms.
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Symptomatic dengue disease progression is broken up into three phases:
febrile, defervescence, and convalescence (Figure 25) (CDC, 2010). The febrile
phase typically lasts two to seven days and is characterized by the presence of a
high grade fever (WHO/TDR, 2009). Other symptomatic manifestations
commonly include rash, headache and/or retro-orbital pain, nausea, vomiting,
dehydration, and muscle and/or joint pain (WHO/TDR, 2009). A ‘saddleback’
fever pattern is not uncommon in dengue patients and should be recognized by
clinicians for proper diagnosis and treatment (Rigau-Pérez et al., 1998). In most
individuals a significant decline in platelet count and concurrent increase in
hematocrit can be observed late in the febrile phase (Figure 26) (WHO/TDR,
2009).

Figure 24. Breakdown of estimated 100 million annual dengue infections
worldwide (Kyle, & Harris, 2008) edited.
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Defervescence, also known as the critical phase, is a 24-48 hour period
during which adverse clinical complications may present (CDC, 2010). The
critical phase is identified with a drop in fever that may progress into below
normal body temperatures in some individuals. Severe symptoms may appear
during this time period include abdominal pain, fluid accumulation, mucosal
bleed, lethargy or restlessness, and hepatomegaly. If left untreated, individuals
may develop severe complications including vascular leakage, severe
hemorrhage, and organ impairment, which may lead shock and possibly death
(WHO/TDR, 2009). Adults and children have been observed to manifest
differently during this time period with vascular leakage predominantly observed
in children and severe hemorrhage observed more often in adults (Whitehorn &
Farrar, 2010; Orthman, 2007).
The last phase of dengue illness is convalescence or re-absorption (CDC,
2010). While the convalescence phase lasts 2-4 days by WHO standards, Lum
and colleagues (2008) have shown that quality of life among dengue patients
does not return to approximately normal levels until almost two weeks after the
beginning of illness. The finding suggests the recovery period for dengue is
much longer than currently proposed (Lum, Suaya, Tan, Sah, & Shepard, 2008).
During the convalescence phase, complications will begin to resolve.
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Figure 25. Phases of dengue infection (CDC, 2010).

Figure 26. “The course of dengue illness” (WHO/TDR, 2009).
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Intrinsic Risk Factors
Intrinsic risk factors for dengue are inherent within a person that
predisposes them to biologically react in a particular manner towards a dengue
infection, such as to develop symptomatic dengue, develop mild manifestations,
or develop life threatening complications. Intrinsic risk factors identified through
epidemiological studies to be significant for development of dengue
complications include age, gender, race, host genetics, co-morbidities, and a
previous dengue infection (Appanna et al., 2010; WHO/TDR, 2009; Kyle &
Harris, 2008; Liu et al., 2008; Ooi, Goh, & Gubler, 2006; Sierra et al., 2006). A
secondary heterotypic dengue infection is the most significant intrinsic risk factor
associated with development of severe dengue complications. Fried and
colleagues (2010), found a 410% increase in odds for development of DHF in
those individuals with a previous dengue infection compared to those with DF.

Diagnostic Criterion
Following outbreaks of dengue hemorrhagic fever in the Philippines and
Thailand during the 1950s, WHO developed criterion for the clinical diagnosis of
dengue (Rigau-Perez, 2006). Since its implementation, the dengue diagnostic
criteria have undergone several revisions with the final version released in 1997
(WHO, 1997). The WHO 1997 dengue diagnostic criteria dichotomously classify
dengue patients into individuals with dengue fever or dengue hemorrhagic fever
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(Figure 27) (WHO, 1997). Dengue hemorrhagic fever is subdivided into four
classes of which classes 3 & 4 are collectively given the term dengue shock
syndrome (WHO, 1997).
After the release of the final revision of the 1997 WHO dengue diagnostic
criteria, researchers and clinicians increasingly expressed dissatisfaction with the
dengue diagnostic criteria (Rigau-Perez, 2006). One of the major complaints
was that individuals were observed to experience severe dengue complications,
but due to the overly stringent dengue classification criteria a DHF classification
was not permitted (Rigau-Perez, 2006).

Figure 27. “Manifestations of Dengue Virus Infection” (WHO, 1997).
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In 2009, the WHO and Special Programme for Research and Training in
Tropical Diseases (TDR) suggested a new set of dengue classification criteria to
address criticism of the 1997 WHO dengue criteria (Figure 28) (WHO/TDR,
2009). The suggested 2009 WHO dengue diagnostic criteria has been recently
accepted as the new standard. Also, the new diagnostic criteria has been
verified to be much more flexible in the classification of patients over the 1997
WHO diagnostic criteria (Barniol et al., 2011).

Figure 28. “Suggested dengue case classification and levels of severity”
(WHO/TDR, 2009) recreated.
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Treatment & Prognosis
Currently, there is no licensed medicine for dengue, and care for
symptomatic dengue infection is palliative with closely managed rehydration
therapy (WHO/TDR, 2009). Immediate clinical management of fluid rehydration
therapy can counteract the effects of plasma leakage, hemorrhage, and organ
impairment. Under trained clinical care, the dengue hemorrhagic case-fatality
rate can drop below 1%; conversely, if left untreated, the case-fatality rate can
climb to 20% (WHO/TDR, 2009; Monath, 2007). Dengue fever is rarely fatal and
typically resolves within a week of symptomatic onset.

Prevention
Personal preventative measures to avoid a dengue infection to date have
revolved solely around reducing contact with vectors as there is currently no
licensed, market ready dengue vaccine. Beyond reducing breeding sites for
dengue vectors in and around the home, an individual can reduce their risk
infection by wearing protective clothing and/or insect repellant. These protective
measures should be closely observed during dawn and dusk when dengue
vectors are most active.
Corresponding in the May 2011 issue of The Lancet, Guy and colleagues
update the ongoing progress of the efforts of several groups to develop a dengue
vaccine. The authors report there are many different techniques being employed
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to develop a dengue vaccine, including cell passage, recombinant DNA
technology, and subunit implementation. In October, 2010, the first dengue
vaccine went into phase 3 clinical trials. This vaccine was developed by Sanofi
Pasteur and is a tetravalent vaccine that has been safely given to 5000 adults
and children. The only disadvantage of this vaccine so far is that two to three
injections are needed to confer protection (Guy, Almond, & Lang,2011).

Laboratory Assays
Dengue Diagnostics
Dengue infections in the acute phase mimic a flu-like illness making
symptomatic clinical differentiation from other infectious diseases found in the
same geographic regions as dengue extremely difficult (i.e. influenza,
leptospirosis, chikungunya) (WHO/TDR, 2009). Dengue diagnostic assays have
been developed to detect several analytes; however, no single assay can yet
detect a dengue infection throughout the disease course. Until a single,
affordable dengue diagnostic assay is developed to detect a current dengue
infection, regardless of disease stage, extensive knowledge of dengue
diagnostics advantages and limitations are needed to correctly use and interpret
assay results. Comprehensive descriptions of technology and methodology for
the detection of viremia, non-structural protein one (NS1), immune response of
Immunoglobulin M (IgM) and Immunoglobulin G (IgG) have been described
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elsewhere (Peeling et al., 2010; Vaughn et al., 2000; Innis, 1997; Vornham &
Kuno, 1997). The following section will provide an overview of the presence of
dengue analytes during dengue disease used in diagnostic assays.
Viremia will be detectable from approximately one day before overt
disease symptoms until the beginning of defervescence, or roughly the fifth day
of symptomatic dengue illness (Figure 29) (PanBioDengue, 2011). The first
serological marker of a dengue infection is non-structural protein one (NS1).
NS1 is present in detectable levels from Day 1 up to Day 9 of illness in both
primary and secondary dengue infections.
The human immune system has a heterotypic response with respect to
anti-dengue immunoglobulin M (IgM) and Immunoglobulin G (IgG), dependent on
primary or secondary dengue infection status. In a primary dengue infection, IgM
can be detected as early as Day 3 of illness, but usually is not detected until Day
5. Immunoglobulin M levels will peak around two weeks from the beginning of
illness and will rapidly decrease to undetectable levels by three months postinfection. Immunoglobulin G will not be detected until early convalescence in a
primary dengue infection, but can remain detectable for decades.
Unlike a primary dengue infection immune response, IgG will typically
precede IgM detection in a secondary heterotypic dengue infection. Anti-dengue
IgG may be detectable by Day 3 of illness, but is generally not until Day 5 or 6.
The IgG antibody response in secondary infection is much greater than the
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primary or past infection and will remain elevated for approximately one month
before returning to levels observed in a primary infection.
The immune response of anti-dengue IgM is varied among individuals with
a secondary dengue infection. Generally the IgM immune response is not
detectable until late in the febrile phase of dengue illness. The detected
response is less than observed in a primary infection and, in a minority of
individuals, no response may be detected. A delayed immune response of antidengue IgM antibodies, during a secondary dengue infection, might occur with
detectable quantities not presenting until 20 days after onset of illness.

Figure 29. “Dengue infection: Immune response” (PanBioDengue, 2011).
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The following sections will introduce the basic mechanics, advantages
and limitations, and briefly discuss result interpretations of each of the commonly
used dengue diagnostic assays. A comprehensive discussion of all dengue
diagnostic assays can be found elsewhere (Peeling et al., 2010; WHO/TDR,
2009; WHO/TDR, 2004).

Viral RNA Detection
One of the most recent advances in dengue diagnostics has been the
development of the reverse transcriptase – polymerase chain reaction (RT-PCR)
assay able to detect the presence of dengue viral RNA in patient samples in real
time (Peeling et al., 2010). Before one can use this new, powerful technology, it
is necessary to extract the viral RNA from the patient sample. Commercialized
kits can be obtained which allow for rapid simultaneous extraction from many
samples. After extraction, samples can be stored for later use or immediately run
in batch groups on the RT-PCR machine, with results being obtained in a few
hours.
Results of the RT-PCR assay are reported as positive for dengue or
indeterminate. A positive result confirms a current dengue infection and will be
reported with the infecting serotype (DENV1-4). An indeterminate result may be
the result of a true non-dengue sample, sample taken too late in dengue disease,
improper handling or processing of patient sample, or improper execution of viral
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RNA extraction and/or RT-PCR method. If results are indeterminate, follow-up
samples should be requested for antigen and/or serology testing to determine if a
person is truly dengue-negative.
Use of RT-PCR in dengue diagnostics allows for timely results that are
highly specific and sensitive. The principal advantage of RT-PCR over other
dengue diagnostic assays is the ability to confirm a dengue diagnosis with a
single patient sample.
Due to the advanced technology and methods used in RT-PCR, there is
need for a substantial initial investment of financial resources to acquire
instrumentation and train personnel. As RT-PCR is only useful during the febrile
phase, the steep financial investment may not be cost-effective for some
institutions as not all patients will arrive at the hospital during the febrile phase.

Non-Structural Protein One Detection
Detection of the dengue NS1 protein is accomplished through a sandwich
enzyme-linked immunosorbent assay (ELISA) (PanBioDengue, 2011). Several
economical commercial assays have been developed and validated using patient
serum samples, however, the use of plasma samples has yet to be established.
As the NS1 protein can be detected from Day 1 up till Day 9 of illness, the NS1
ELISA provides a bridge to detect a dengue infection throughout disease course
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as there is a potential gap between reduction of viremia and increase in dengue
immunoglobulin (Dussart et al., 2006).
Results of the NS1 kit are reported as positive, fail to detect, or equivocal
(PanBioDengue, 2011). Interpretation of a positive result is that the dengue NS1
protein has been detected in the patient’s serum, which is indicative of a current
dengue infection. However, further serology testing on a follow-up serum sample
should be completed to confirm a dengue diagnosis as there are limitations to the
assay. A fail to detect result means that NS1 to dengue has not been detected;
however, this does not rule out a dengue infection. Samples with results of fail to
detect and equivocal should undergo a dengue IgM ELISA to further exclude a
dengue diagnosis.
The NS1 ELISA is rapid and useful for detecting a current dengue
infection when RT-PCR and IgM ELISA analytes may not be present in
detectable quantities. The NS1 ELISA cannot by itself confirm a dengue
diagnosis but can suggest the possibility of a current dengue infection. Limiting
the diagnostic capability is serological cross-reactivity between dengue and other
flaviviruses (Peeling et al., 2010).

Immunoglobulin M Detection
Detection of dengue IgM antibodies is accomplished through a capture
ELISA. Like the NS1 ELISA, the IgM ELISA has been developed using patient
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serum samples. As anti-dengue IgM antibodies are present in detectable levels
from approximately Day 5 of illness up to three months post-infection, they
provide an ideal means of identifying individuals with a recent dengue infection
(Peeling et al., 2010).
Results of the IgM ELISA are reported as positive, fail to detect, and
equivocal. A positive result indicates that the IgM to dengue has been detected.
Equivocal results should be re-run with a follow-up sample. The interpretation of
a fail to detect result is dependent on the onset date of clinical symptoms. If the
sample was collected 20 days after dengue-like disease onset, then the patient
most likely did not have non-dengue. However, if the sample was collected less
than 20 days from onset of dengue-like clinical symptoms, then the result is
reported as IgM to dengue not detected, and a request is made for a follow-up
sample as the patient may have not yet seroconverted.
The dengue IgM ELISA is affordable, easy to run, and does not require
large investments of financial resources to implement. However, due to the
inherent duration of the anti-dengue IgM antibodies in the body, dengue cannot
be confirmed with a single positive IgM ELISA. To confirm a dengue diagnosis
using IgM ELISA, two temporally spaced patient samples must be obtained. As
anti-dengue IgM titers do not reach their peak until approximately two weeks
after onset of symptoms, an increasing trend or seroconversion will confirm a
dengue diagnosis in temporally-spaced paired-samples.
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Immunoglobulin Detection
The dengue haemagglutination inhibition (HI) quantitates the patient
serum anti-dengue immunoglobulin (Ig) irrespective of Ig isotype (i.e. IgA, IgM,
IgG) (De Paula & Fonseca, 2004). Recently, with the development of sensitive
IgG and IgM ELISA, HI popularity in dengue diagnostics has decreased as it is a
time and labor intensive process (minimum two days). HI also requires paired
patient sera with removal of non-specific inhibitors and agglutinations from sera.
However, minimal equipment to complete the assay, reliability, and that the
assay is well-standardized keeps the dengue HI assay as the gold standard in
determining if a dengue infection is primary or secondary in nature. The
distinction between primary and secondary dengue infection is possible as
sustained levels of serum anti-dengue Ig are significantly different in primary and
secondary cases.
Findings will be reported as positive for dengue with a primary or
secondary dengue infection or dengue not detected. Patient samples with an
acute sample HI titer <1280 and a convalescence sample HI titer <2560 are
considered primary infections. Secondary infections will have an acute sample
titer of <2560 and a convalescence sample titer of >2560 (De Paula & Fonseca,
2004).
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Laboratory Dengue Confirmation
Currently there is no laboratory assay capable of detecting a dengue
infection regardless of disease progression. Without this universal dengue tool,
there is a need to fully understand dengue diagnostics to aid in diagnosis and
correctly report cases for surveillance. A single sample positive RT-PCR result
can confirm a dengue diagnosis (Figure 31) (Peeling et al., 2010). If the RT-PCR
result comes back as indeterminate, then antigen and serology tests must be
completed to confirm a dengue diagnosis. Potential cross-reactivity of antigens
and long lifespan of serological components make necessary the need to obtain
two positive results to confirm a dengue diagnosis. The use of one positive
sample of antigen and serological dengue assays can suggest a dengue
infection, but it is an incorrect practice to laboratory confirm a dengue infection.

*Requires paired samples.

Figure 30. Criteria to laboratory confirm a dengue infection (Peeling et al.,
2010).
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METHODOLOGY
Study Location
The study location was Federal Hospital Ampang in Ampang, Selangor,
Malaysia.

Country
Malaysia, located in Southeast Asia, is comprised of an area slightly larger
than the US state of New Mexico at 329,847 sq km, is split into the two distinct
land masses of Peninsular Malaysia and Borneo Malaysia by the South China
Sea (CIA, 2011). The majority of Malaysia experiences a tropical climate;
however, sub-tropical conditions exist in the interior mountains in both Peninsular
and Borneo Malaysia. Annual monsoons drive changes in climatic conditions,
typically seen in the southwest from April to October, and the northeast from
October to February (CIA, 2011). Total annual rainfall can accumulate to
2,427millimeters (95.6 inches) in Peninsular Malaysia, though rainfall totals can
be double this amount in Borneo Malaysia (WWIS, 2011). Annual average
temperatures have low variability throughout Malaysia; Kuala Lumpur annual
high temperatures range from 31.5⁰C to 33.2⁰C (88.7F to 91.8F), and low
temperatures range from 22.5⁰C to 23.9 ⁰C (72.5F to 75.0F) (WWIS, 2011).
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The 2010 Malaysian Census reported the Malaysian population to be 28.3
million with a 1.04 male/female ratio. The main racial backgrounds of the
Malaysian population include: Malays (60.3%), Chinese (22.8%), Indians (6.8%),
and Others (10.0%, including expatriates). The Malaysian population age
groupings are skewed left with 27.2% aged 0-14, 68.1% aged 15-64, and 4.7%
aged 65 and over in 2010 (Dr. J. Sathar, personal communication, March 2011).
The average Malaysian household annual income is an estimated
Malaysian Ringget $44,500 (~US$14,700) with 5.1% (est. 2002) of the population
below the poverty line (CIA, 2011). Literacy rate for the Malaysian population is
88.7%, with females staying an average of 13 years, one year longer than males,
in formal education (CIA, 2011).
Malaysia is divided into 13 federal territories, of which the nine western
federal territories are the most populated (Figure 31) (Encyclopedia Britannica.
2009).

City
The formal capital city, Kuala Lumpur, resides in Kuala Lumpur Federal
Territory in southwestern Peninsular Malaysia. Surrounding Kuala Lumpur
Federal Territory is the most populous federal territory, Selangor, with 5.1 million
individuals in 2010 (Dr. J. Sathar, personal communication, March 2011).
Selangor, save the new federal territory and governmental capital of Putra Jaya
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(growth rate: 17.8%), is the fastest growing federal territory with a growth rate of
3.17% in 2010 (national growth rate: 2.17%) (The World Bank, 2011). The
District of Ulu Langat is the westernmost of the 9 districts which comprise
Selangor.

Figure 31. Population density of Malaysia in 2009 (Encyclopedia Britannica.
2009).

Hospital
Federal Hospital Ampang is located in the subdivision of Ampang, one of
seven subdivisions which makeup the District of Ulu Langat. Statistics from the
2010 Malaysian Census for the District of Ampang will not be available till 2012
(Dr. J. Sathar, personal communication, March 2011). In 2000, the District of
Ampang population numbered 357,925 which broken down by racial background:
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Malay 45.2%, Chinese 40.2%, Indian 8.5%, Other 6.1% (Dr. J. Sathar, personal
communication from Ministry of Statistics, March 2011).
The Malaysian healthcare system is similar to the United States two-tier
system of public and private services (MMOH, 2011). Easy access to healthcare
is provided to anyone in a public hospital after a co-pay of Malaysian Ringget $1
(~US$0.33 March 2011). Selangor currently has 20 private hospitals and 12
public hospitals (MMOH, 2011); Federal Hospital Ampang is a public hospital
with 560 beds (K. Khalid, personal communication from Hospital Ampang, March
2011). Opening in 2006, Hospital Ampang is modern 8-story structure complete
with a two-story out-patient clinic, tri-stage (general, semi-critical, and critical)
emergency department, comprehensive and rapid clinical laboratory with modern
equipment, blood bank, and transplant capabilities. Hospital Ampang retains a
two-tiered patient room structure with dormitory style multi-bed wards throughout
the hospital and private rooms located on the 8th floor.

Dengue Ward
Dengue has become a major burden to the healthcare system in Malaysia.
At Hospital Ampang and other hospitals in Malaysia (e.g. Klang Hospital), to
facilitate a standard of care for individuals suspected or confirmed to be infected
with dengue, a dengue ward has been established. Admitted patients from the
emergency department, clinics, other departments in Hospital Ampang and
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surrounding area hospital transfers who are suspected or have been confirmed
to have dengue, are transferred to the dengue ward as standard hospital
procedure. Patients who are in critical condition (i.e. hypovolemic shock), will be
transferred to the Intensive Care Unit (ICU); however, after dengue cases have
been stabilized, they are transferred back to the dengue ward. The dengue ward
is a dormitory style ward with 28 beds (2 isolation rooms) separated by gender.
Under epidemic conditions, additional beds can be included as beds are
generously spaced. In-ward office and kitchen space allow for continued
presence of medical staff.
Due to the cyclical pattern of dengue outbreaks, dengue patient loads will
vary potentially leaving the majority of the dengue ward unused. To ensure the
hospital efficiently uses all resources, patients without dengue will be transferred
to the dengue ward for care. Patients transferred typically have infectious
diseases (tuberculosis, HIV, leptospirosis, etc.); although chronic diseases (heart
disease, diabetes, etc.) can also be transferred. To rapidly identify dengue cases
wall name tags above the patient beds are green for dengue and blue for nondengue.

Treatment & Care
Treatment and care of dengue ward patients are performed by hospital
administration, senior doctors, junior doctors, head nurses (‘Sisters’), nurses,
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junior nurses, medical technicians, student nurses, and janitorial staff. Daily
morning medical ‘rounds’ are completed by the single senior doctor overseeing
the ward, two to three junior doctors (known as ‘housemen’), head nurses, and
nurses. Housemen are rotated between medical wards on a monthly schedule
for comprehensive medical training. Housemen and nurses are responsible for
recording all medical information in the hospital electronic database. Three carts
with laptops and wireless internet allow for bedside note taking, while three
additional desktops provide comfort for more lengthy entries. Hardcopy medical
charts including vital statistics are kept updated at each patient’s bedside by
junior nurses and student nurses in case of power or database failure. Hardcopy
charts are stored upon patient discharge.
Junior doctors and/or nurses draw blood for clinical assessment four times
a day at the six o’clock and twelve o’clock hours or as directed by the senior
doctor. Clinical laboratory tests typically include blood, kidney and liver profiles.
A blood profile measures venous levels of the following: hemoglobin, hematocrit,
platelet count, total white cells, neutrophils, lymphocytes, monocytes, eosinophils
and basophils. A liver profile assesses venous levels of total bilirubin, alkaline
phosphatase, total protein, albumin, globulin and alanine aminotransferase. A
kidney profile indicates venous levels of urea, sodium, potassium chloride and
creatinine.
All patients are administered intravenous hydration saline solution, which
are monitored to ensure patients are properly hydrated throughout disease
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course. Blood transfusions and platelet transfusions are no longer considered for
dengue treatment in the dengue ward (practice changed in early 2010); different
practices may be present in the ICU. The tourniquet test is not administered as
standard dengue diagnostic procedure. Patients are not discharged before the
end of the 48 hour defervescence phase of disease and may remain admitted for
longer periods of time (i.e. days or weeks) if complications arise (e.g. severe viral
hepatitis).

Study Population
The study is a subset within a larger cross-sectional medical microbiology
study entitled: Genetic and Immunological Profiles during the Progression of
Dengue Disease (further referred to as ‘source study’). The source study is
under the direction of Professor Dr. Shamala Devi of the Medical Microbiology
Department, Faculty of Medicine, at the University of Malaya in Kuala Lumpur,
Malaysia. The source study was conducted from June to December 2010.
To fully understand this study and the study population, it is necessary to
first describe the purpose and study design used in the source study. The
source study was envisioned to fill a gap in the current dengue literature of a
comprehensive clinical and laboratory profile of dengue disease to aid in the
discovery and development of diagnostic assays, treatment, and vaccine.
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The source study targeted the fraction of the dengue infected population
who manifest with complications requiring medical intervention, as they are most
in need of medical breakthroughs.
The source study employed a cross-sectional design; however, the design
does not fit the classical form of the study type. Infectious diseases are unique
from chronic diseases in that if a patient develops, say dengue, it is known they
have been exposed to the dengue virus when they arrive at a hospital for
treatment. Consequently, the source study population consists of all new dengue
cases, beyond patients who were suspected to have dengue on study
recruitment and were later diagnosed with a similar manifesting disease (e.g.
leptospirosis). Exposure is therefore not regarded in the classical sense as
exposure to the infecting agent or not, but is perhaps a pre-existing condition,
such as previous infection with dengue virus that can be determined through
laboratory analysis. Outcome is also dissimilar to the classical case and control.
The outcome might be defined, for example, as monocyte count or presence and
absence of hemorrhage. The discharge diagnosis was used in the source study.
The source study design also deviates from the classical form of a crosssectional design by the inclusion of a longitudinal dynamic in data collection. As
the purpose of the primary study was to develop a profile of dengue disease
progression, patients were followed throughout their hospitalization. For the
source study, patient clinical and laboratory data was collected at three time
points with one point in each of the three phases of dengue disease (febrile,
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defervescence, and convalescence). Even with the longitudinal dynamic of the
source study, the design remains a cross-sectional study due the exposure and
outcome of interest being determined at the same time.
The present study only assesses patient data within the defervescence
phase of illness. Demographics of the source study are presented in the
RESULTS section.

Study Design
The study design is an analytic cross-sectional study that has been subset
within the source study completed from June to December 2010. Subsetting the
study within the source study allows for efficient use of resources as preliminary
empirical justification for a standalone study has not yet been demonstrated.
Few epidemiological studies have investigated the relationship of monocytes
during dengue disease. No studies were found in the literature review that
examined the association of monocytes with primary and secondary dengue
infection status.
The target population of the study includes all individuals aged 15 years or
older, who are susceptible to dengue and would develop severe complications as
a result of infection, and live in Malaysia. The target population is the population
to which the study findings would ideally be inferred. The source population, the
population from which individuals will be selected for study inclusion, includes
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individuals aged 15 years or older that have acquired a dengue infection and
came to Hospital Ampang for medical treatment from June to December 2010.
The study eligible population is comprised of those individuals from the source
population who meet the study inclusion and exclusion criteria.
Study inclusion criteria included admission to Hospital Ampang for
dengue, and age of 15-17 years with written parental permission, or age of 18
and above. The study exclusion criteria excluded from the study those potential
study participants that did not have the ability or willingness to provide informed
consent in English, Malay, Chinese or Tamil; did not have consenting permission
of the overseeing clinician for patient inclusion; or did not have a recorded
venous absolute monocyte count in the Hospital Ampang computerized patient
database for the defervescence stage of dengue disease.
The study inclusion/exclusion criteria have allowed for targeting of a study
population that will allow for ideal analysis of the association of interest.
Defervescence is the critical time period during which severe dengue
complications manifest. Restricting the study to only hospitalized patients during
defervescence, permits assessment of the relationship of interest on a highly
burdened population that may provide insights that may not be observable in
other populations or dengue disease phases.
Dengue literature has primarily focused on individuals less than 15 years
of age due to the suspected fragility of their undeveloped capillaries resulting in
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increased risk for development of severe dengue manifestations (Kyle & Harris,
2008). The UN defines “children” as those less than 18 years of age (UN, 1990);
however, for statistical purposes the UN has defined “youth” as those between
the ages of 15-24 years (UNESCO, 1985). A study population consisting of
youth and adult, non-youth was recruited for the study as severe dengue has
increasingly effected these populations.
Unlike other infectious diseases (i.e. human immunodeficiency virus or
tuberculosis), dengue is a non-chronic disease making the study population
composed of all incidence cases. In this study, the study exposure is not defined
as having been exposed to the disease agent, but having a current primary or
secondary dengue infection. The use of the hemagglutinin inhibition laboratory
assay allows for determination of a patient’s dengue infection status (primary or
secondary).
Studies have observed that a previous dengue infection is a risk factor for
development of complications during dengue disease. Biological pathway
hypotheses have suggested that the primary dengue infection alters the immune
system response to a secondary heterotypic dengue infection. Using dengue
infection status as the study exposure will permit observation of the primary
objective on whether or not the predisposition has an association with venous
absolute monocyte count.
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Unlike the classical epidemiologic cross-sectional study outcome of case
and control, the study outcome is a difference in the venous absolute monocyte
count. The study outcome has not been dichotomized by a cut point because no
previous estimate of the relationship under investigation was found in the
literature review. The study’s null hypothesis is that there is no difference in
venous absolute monocyte count by dengue infection status. Absolute monocyte
count is a reported clinical laboratory result given as part of a normal blood
profile. As a blood profile is a standard set of clinical laboratory assays
administered to dengue patients in Hospital Ampang, most dengue patients were
expected to undergo a blood profile during defervescence. Monocytes are of
interest due to their role in both innate and adaptive immunity.
The literature review identified several risk factors which needed to be
included in the study analysis due to their association with the study exposure
and outcome, not being part of the hypothesized causal pathway, and potential
for being present in different degrees between study groups. These risk factors
are race, age, and gender. Race was categorized by the major race observed in
the Malaysian population, which are Malay, Chinese, Indian, and Other. Gender
was categorized as male or female. A review of the dengue literature found
many different cuts points by which age was categorized (groupings of 2, 3, 5, &
10 years) with no clear indication given for the reasoning behind the selection.
Whereas studies investigating children with dengue used smaller interval cut
points, studies investigating adults tend to categorize the age demographic by
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groupings of 5 or 10 years. The study assessed the age demographic by both 5
and 10 year groupings; however, only the 10 year groupings are displayed and
assessed in the regression analysis as no significant results were observed using
the 5 year grouping. Age was categorized as 15-24 years, 24-34 years, 35-44
years, and 45 years and above. The last grouping was set as 45 years of age or
above because few individuals were recruited for the study above 55 years of
age. Age was also assessed as a continuous variable to determine if the cut
points were creating or masking an association.
Known risk factors which were unable to be assessed in the analysis
included infecting viral serotype, socioeconomic status, and education. No data
was available on these risk factors as current practice at Hospital Ampang does
not take this information from the patient and the hospital laboratory does not
possess the necessary assay.
To consider the influence of these unattained risk factors a surrogate
variable was used. As Hospital Ampang is a new hospital (opened in 2006) and
is a transfer hospital for other major diseases (i.e. thalassemia), there is potential
that patients will travel themselves or be transferred to Hospital Ampang if they
have severe dengue complications. Distance between patient residence and
Hospital Ampang, dichotomized at 12.5 kilometers was assessed for being a risk
factor. The 12.5 kilometer radial boundary was arrived at by averaging the
distance between Hospital Ampang and the closest public hospitals. This cut-off
value will allow for approximate dichotomization of those individuals who are
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travelling to the nearest hospital and those who are travelling extra distance to
receive care at Hospital Ampang. The use of this surrogate variable was not
seen in the literature review and careful consideration is needed whether or not
to include in the final regression models as results maybe artificial.
The study secondary objective was to assess the relationship of absence
or presence of hemorrhage/vascular leakage with venous absolute monocyte
count. The literature review found few studies in which monocytes (absolute or
percent) were found to be significantly associated with the outcome of the study,
which is the absence or presence of hemorrhage/vascular leakage, when using
the standard dengue classification criteria. A hypothesis was formed that
differences in absolute monocyte count maybe associated with severe dengue
complications, but is unobservable or masked most of the time when using the
dengue diagnostic criteria as an outcome. Excessive effusion is the primary
cause of death from dengue with vascular leakage and hemorrhage being the
principal manifestations.
The secondary objective analysis uses the absence or presence of
hemorrhage/vascular leakage as an outcome with the aim to determine if an
association exists with absolute monocyte count. Hemorrhage was defined as
presence of spontaneous gum bleed, epistaxis, menorrhagia, hematemesis,
subconjunctive hemorrhage, renal hemorrhage, or melena. Vascular leakage
was defined as presence of pleural effusion, ascites, increase or decrease of
hematocrit by 20%, hypotension (systolic blood pressure <90mmHg), or
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narrowed pulse pressure (<20 mmHg) (WHO/TDR, 2009). Risk factors for the
association included age, race, gender, dengue infection status (primary or
secondary), and distance from patient’s residence to Hospital Ampang.
Loss to follow-up in the study could have occurred as a result of the
patient no longer wanting to be part of the study, and medical staff not taking
study samples. To ensure patients continued to take part in the study, study
recruiters took significant effort to explain to the patient the value of the study.
As recruiters were in the hospital every weekday for several hours, they were
encouraged to talk with participants providing them with anti-dengue educational
material made and provided by the Malaysian Ministry of Health. This interaction
served to provide an opportunity for the patient to ask any further questions
about the study and dispel any worries about the risks of study participation the
patient may have developed.
Loss to follow-up as a result of medical staff not taking samples
necessitates maximum input on study staff to overcome the demanding and
variant nature of medical care. The primary obstacle to overcome occurred at
the beginning of every month, when junior doctors transferred assigned wards.
This required study staff to inform and then train the new medical staff on the
procedures of the study. To ensure minimum loss to follow-up, the study blood
draws were incorporated within the established daily blood taking routine. After
the study staff had recruited patients they would label the appropriate blood
collection tubes and place them in order on the blood collection cart, which was
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used for all hospital blood collection. The study staff then verbally communicated
with the doctors on how many tubes and patients needed to be drawn for the
study during the next scheduled collection time.
No financial incentive was provided to participants. To reduce the risk of
potential infection and discomfort of the patient, the study blood draw was added
on to the planned hospital blood draw. Taking blood samples in this manner
allowed for patients to participate without having to endure any additional needle
sticks than what was required by the hospital. The benefit provided by the study
was to report the results of the dengue RT-PCR testing conducted at the
University of Malaya laboratory. The RT-PCR testing was part of the primary
study design and the patient was not charged for testing. RT-PCR results were
made available to ward doctors to explain results to patients. Hospital Ampang
did not have RT-PCR capabilities, but patients who did not want to participate
could obtain dengue infection status through anti-dengue IgM testing routinely
completed by the Hospital Ampang clinical laboratory. No additional needlesticks and free laboratory testing allowed for the benefits of study participation to
outweigh the risks to the study participation.
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Data Collection
Data collection for both the source study and present study were carried
out using the same protocol. The following section presents an overview of the
protocol for clinical and laboratory data collection.

Clinical Data
After patients were admitted to the dengue ward in Hospital Ampang,
study recruiters approached ward doctors to establish medical consent for study
participation. If the doctor gave medical consent, the patient was approached for
informed consent. After successful recruitment of the study participant, the
hospital identification number was recorded on a standardized study participant
clinical data form. The patient clinical information was obtained using the study
participant hospital identification number in the hospital electronic database
system. Use of the standardized clinical data form allowed for consistent
recording of all study participant data. The study participant clinical data forms
were transferred back to the University Malaya laboratories of Professor Dr.
Shamala and input into a database using Microsoft Excel© (Redmond, WA). The
electronic database was saved on a single computer and backed up using an
external hard drive.
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Laboratory Data
The participant study blood sample tubes were collected immediately from
the dengue ward blood draw cart after medical staff had completed drawing
blood. Patient blood collection tubes were then stored in an onsite 4⁰C
refrigerator before being transferred by cooler and gel freezer pack to the
University Malaya laboratory of Professor Dr. Shamala Devi within 4 hours of the
blood draw. Upon arrival the samples were immediately processed,
appropriately aliquoted, and stored at -80⁰C for long-term storage. Received
samples were recorded in a hard copy notebook to document their presence in
storage.
Samples were assessed for the presence of dengue viral RNA, dengue
NS1 protein, and anti-dengue immunoglobulin M and G. Discussions and
protocols for the use of dengue diagnostic assays can be found elsewhere
(WHO/TDR, 2004; PanBioDengue, 2011). Results of the assays were recorded
in an electronic database and back-up on an external hard disk.

Statistical Analysis
The laboratory and clinical databases were cleaned and analyzed in
SAS© (Cary, NC). Frequency and univariate procedures were used to identify
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missing values and outliers. All suspected errors were checked against hard
copy documents.
Chi-square tests for independence and Fisher’s exact test, used to
examine if two populations contain the same proportion of observations of a
single variable, and independent sample t-tests, used in the comparison of two
populations’ mean on a single variable, were used in the assessment of variables
across study populations. Linear and logistic regression models were used in the
assessment of the study primary and secondary objectives, while allowing for
adjustment of the effects from independent risk factors on the relationship of
interest.

Sample Size Calculation Statement
A sample size calculation is a necessary component of an epidemiological
study and should be carried out during the planning phase of the study to ensure
efficient use of limited public health resources. As this study was a subset within
the source study, it was not the main consideration during study planning phase.
A power calculation was conducted retrospectively to determine if sufficient
power existed for the analysis (see RESULTS).

85

RESULTS
Retrospective Power Calculation
The retrospective power calculation was completed to ensure that there
are enough study participants to detect an association above a chance finding
using estimates extracted from the literature. While not ideal, the retrospective
power calculation is an acceptable practice, but should be avoided if possible.
Literature on youth or adult population monocyte levels during
defervescence by primary and secondary dengue infection status was not found
in the literature review. In fact, monocyte levels by primary and secondary
dengue infection status were not found among any population. This again
illustrates the need for the study, but also the difficulty in finding an acceptable
estimate to base the retrospective power calculation.
All secondary heterotypic dengue infections do not result in development
of dengue hemorrhagic fever, while some primary dengue infections have severe
complications. The use of the dengue clinical diagnostic classification in the
study retrospective power calculation is imperfect, but remains the closest
available option as secondary heterotypic dengue infection has been consistently
observed to be a risk factor for severe dengue manifestations (WHO/TDR, 2009).
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Green and colleagues (1999) presented findings of absolute monocyte
count among 51 Thai children (<15 years of age) by clinical dengue diagnosis
(dengue fever (n=29) and dengue hemorrhagic fever (n=22)) during
defervescence. The dengue fever population had an average absolute monocyte
count of 193 ± 119, while the dengue hemorrhagic fever population was 226 ±
196.
The power calculation employed an independent sample for means twosided formula, as previous hypothesis were not available to justify the use of a
one-sided test. A 0.05 significance level, or odds that the observed is due to
chance, was used. Population estimates of 193 and 226, along with a standard
deviation for the population of 152 (averaged, ((119*29) + (226*22)/51)) were
used from Green and colleagues (1999) findings. With a study population of 197
participants, the estimated power is 0.87. This indicates that the odds that an
association will be observed when one actually exists are 87%. The power
calculation was completed using SAS® and checked in an online power and
sample size calculator (Statistical Solutions, 2011).

Demography
To aid in determining the external validity of the study, the source
population and source study demography will be described first followed by the
study demography to allow for comparisons. The source population of the study
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included all individuals above the age of 15 years who would come to and would
be hospitalized at Hospital Ampang for a dengue infection from June to
December 2010. Information on this exact population could not be obtained;
however, demographic information was acquired on all Hospital Ampang dengue
patients, in- and out-patient, during the 2010 calendar year. While not the exact
source population for the primary study, the information provides a very good
estimate on the entire population that would come to Hospital Ampang for
treatment from a dengue infection.
The source population consisted of 16,367 cases of dengue with one
death reported from Hospital Ampang during the 2010 calendar year. Deaths
from dengue remain very low at Hospital Ampang with only two and three
occurring in 2008 and 2009, respectively. The single 2010 dengue death at
Hospital Ampang occurred before the June start of the study. Dengue cases at
Hospital Ampang were 53.3% male and 62.0% Malay; 22.8% Chinese; 9.8%
Indian; and 5.4% Other during 2010. The age distribution was 33.4% aged 15 to
24 years, 32.3% aged 25 to 34 years, 17.9% aged 35 to 44 years, and 16.5%
aged 45 years and older (Table 1) (J. Sathar, personal communicate, April 2011).
During the data collection time period of June through December 2010,
the source study approached 381 patients at Hospital Ampang who met the
study inclusion/exclusion criteria, of which, 94 declined to participate. Patients
who refused to participate (Source Study Refusals) tended to be male (53.3%);
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Malay (62.0%); aged 15 to 24 years (35.7%); and lived within 12.5 km of Hospital
Ampang (83.9%) (Table 1).
With a participation rate (of those individuals who met inclusion/exclusion
criteria and were asked to participate, those who agreed) of 80.2%, there were
287 individuals who entered the source study (study entrants). Four individuals
refused to participate after they entered the source study and the medical staff
did not draw blood serum samples for seven samples resulting in the
participants’ inability to contribute to the study data. With a retention rate (of
those individuals who entered the study, those who contributed to the study data)
of 96.2%, the final number of study participants for the source study was 276.
Source study participants were more likely to be male (63.0%); Malay (61.6%);
aged 15-24 years (38.1%); and lived within 12.5 km of Hospital Ampang (83.0%)
(data not shown). Source study participants were admitted to Hospital Ampang,
on average, 4.08 ± 1.71 days after self-reported onset of illness and had a length
of hospitalization of 4.26 ± 2.57 days. Further descriptive statistics on the source
study by blood profile, liver profile, kidney profile, and vital statistics profile are
presented in Appendix B.
Of the source study participants, 22 were not diagnosed with dengue.
Non-dengue diagnosed individuals were more likely to be male (81.8%); Malay
(68.2%); adult, aged 24-34 years (45.5%); and lived within 12.5 km of Hospital
Ampang (86.4%) (data not shown). Source study participants not diagnosed with
dengue were admitted to Hospital Ampang, on average, 4.19 ± 3.12 days after
89

self-reported onset of illness and had a length of hospitalization of 4.47 ± 1.92
days.
Of the source study participants, 248 were diagnosed with dengue and
above the age of 15 years. Dengue diagnosed individuals were more likely to be
male (63.0%); Malay (61.6%); aged 15-24 years (38.3%); and lived within 12.5
km of Hospital Ampang (83.0%) (Table 1). Source study participants diagnosed
with dengue were admitted to Hospital Ampang, on average, 4.07 ± 1.58 days
after self-reported onset of illness and had a length of hospitalization of 4.24 ±
2.61 days.
The study was a subset of the data from the source study by restricting
the study population to only those participants who were laboratory confirmed
with a dengue infection, and that had a recorded absolute monocyte value during
the defervescence phase of illness. The study population consisted of 197
participants of which the majority were male (62.7%); Malay (64.0%); aged 25-34
years (46.3%); and lived within 12.5km of Hospital Ampang (81.2%) (Table 1).
Study participants were admitted to Hospital Ampang on average, 4.07 ± 1.55
days after self-reported onset of illness, and had a length of hospitalization of
4.54 ± 2.73 days.
The chi-square test for independence was used to examine if the study
population, source study participants (with a dengue diagnosis), and source
study refusals contained the same proportion of observations by gender, race,
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age, and distance between patient residence and Hospital Ampang. No
significant differences were detected among the populations at the 0.05 level of
significance.

Table 1. Demographics of Study Participants, Source Study Participants by
Dengue Diagnosis, Source Study Non-Participants, and Source Population in
Hospital Ampang, Selangor, Malaysia, 2010.
Source
Source
Source
Study
Study
^
Study
#
Participants
Population
Participants*
Refusals
N
N
N
N
%
%
%
%
Total
197
77.6
248 90.0
94 100
16367 100
Gender
Male
124
62.9
152 61.3
49 53.3
9503 58.1
Female
73
37.1
96 38.7
43 46.7
6864 41.9
Race
Malay
126
64.0
151 60.9
57
62
9272 56.7
Chinese
44
22.3
57 23.0
21 22.8
3678 22.5
Indian
13
6.6
17
6.9
9
9.8
2081 12.7
Other
14
7.1
23
9.3
5
5.4
1336 8.2
Age (years)
15-24
74
37.6
95 38.3
30 35.7
4495 33.4
25-34
69
35.0
85 34.3
25 29.8
4335 32.3
35-44
28
12.2
36 14.5
15 17.9
2399 17.9
>45
26
13.2
32 12.9
14 16.7
2213 16.5
&
Distance
≤ 12.5
160
81.2
203 81.9
73 83.9
> 12.5
37
18.8
45 18.2
14 16.1
* Dengue clinical diagnosis only.
#
Difference to total reflect information refusal.
^
Hospital Ampang in-patient and out-patient dengue cases during 2010;
Includes 2,925 children (<15 years); Total for Age excludes children.
&
Distance between patient residence and Hospital Ampang in kilometers.

The source population was not included in chi-square analysis for gender
and race as 17.9% of source population summary statistics obtained consisted of
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children whose information could not be separated from those aged 15 years and
older. Chi-square tests for independence did not detect a significant difference
between the source population and all other populations in Table 1 by age.
The majority of participants within the study population had contracted a
secondary dengue infection (79.2%) (Table 2). The gender ratio (male: female)
was 1.56:1.0 and 1.74:1.0 for secondary and primary dengue infections,
respectively. Among both primary and secondary dengue infection populations,
the majority of participants were male, Malay, and lived within 12.5 km of
Hospital Ampang. The majority of individuals experiencing a primary dengue
infection were aged 25-34 years, whereas those experiencing a secondary
dengue infection were aged 15-24 years.
Using chi-squared test for independence and fisher’s exact test were
appropriate, there was no significant difference detected between infection status
populations by gender, race, or distance between residence and Hospital
Ampang. A significant difference was detected between primary and secondary
infections among those aged 45 years and older.
Study participants stratified by dengue infection status were admitted to
Hospital Ampang, on average, 4.17 ± 1.75 (primary) and 4.04 ± 1.49 (secondary)
days after self-reported onset of illness and had an average length of
hospitalization of 5.15 ± 3.93 (primary) and 4.39 ± 2.30 (secondary) days.
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Table 2. Study Participants Demographics by Dengue Infection Status and
Effusion Status in Hospital Ampang, Selangor, Malaysia 2010.
Dengue Infection Status

Effusion Status
Total

Primary
N
Total
Gender
Male
Female
Race
Malay
Chinese
Indian
Other
Age
15-24
25-34
35-44
>45

%

Secondary

Absence

Presence

N

N

%

N

%

%

N

%

41 20.8

156

79.2

115 58.4

82

41.6

197

100

25 61.0
16 39.0

99
57

63.5
36.5

77 67.0
38 33.0

47
35

57.3
42.7

124
73

62.9
37.1

24 58.5
12 29.3
4 9.8
1 2.4

102
32
9
13

65.4
20.5
5.8
8.3

75 65.2
24 20.9
8 7.0
8 7.0

51
20
5
6

62.2
24.4
6.1
7.3

126
44
13
14

64.0
22.3
6.6
7.11

15 36.6
19 46.3
5 12.2
2 4.9

59
50
23
24

37.8
32.1
14.7
15.4 ‡

39
42
17
17

33.9
36.5
14.8
14.8

35
27
11
9

42.7
32.9
13.4
11.0

74
69
28
26

37.6
35.0
14.2
13.2

81.4
18.6

95 82.6
20 17.4

65
17

79.3
20.7

160
37

81.2
18.8

&

Distance
≤ 12.5
33 80.5 127
> 12.5
8 19.5
29
P-value: † <0.05; ‡ <0.01
&

Distance between patient residence and Hospital Ampang.

Stratification of the study population found the majority of participants
were free of hemorrhage/vascular leakage manifestations (57.3%) (Table 2).
The gender ratio (male: female) was 2.03:1.0 and 1.34:1.0 for absence and
presence of hemorrhage/vascular leakage, respectively. Among both study
categories of effusion status, the majority of participants were male, Malay, and
lived within 12.5 km of Hospital Ampang. Among those individuals with absence
of effusion the majority were aged 25-34 years; whereas among those individuals
with presence of effusion the majority were aged 15-24 years.
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There was no significant difference detected between effusion status
populations by gender, race, age, or distance between residence and Hospital
Ampang. Study participants stratified by effusion status were admitted to
Hospital Ampang, on average, 4.04 ± 1.41 (absence) and 4.10 ± 1.72 (presence)
days after self-reported onset of illness and had an average length of
hospitalization of 4.67 ± 2.95 (absence) and 4.37 ± 2.39 (presence) days.

Co-Morbidities
Overall, co-morbidities were only observed in 7.6% of the study population
(Table 3). Hypertension was the most observed co-morbidity in the population
(4.1%), followed by diabetes mellitus (3.1%). One individual was found to have
ischemic heart disease. No chronic kidney disease or congestive heart failure
was observed.
Table 3. Study Participants Co-Morbidities by Dengue Infection Status and
Effusion Status in Hospital Ampang, Selangor, Malaysia 2010.
Infection Status
Primary

Study Participants

N
%
41 20.8

Effusion Status

Secondary
N
%
156 79.2

Absence
N
%
115 58.4

Total

Presence
N
%
N %
82 41.6 197 100

Diabetes mellitus

2

4.9

4

2.6

3

2.6

3

3.7

6 3.1

Hypertension

2

4.9

6

3.9

4

3.5

4

4.9

8 4.1

0

0.0

1

0.6

1

0.9

0

0.0

1 0.5

4

9.9

11

6.9

8

7.0

7

8.5

15 7.6

Other

*

Total Diseased
*

Chronic kidney disease, congestive heart failure and ischemic heart disease.
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Manifestations
Among the study population, the most common manifestations were
nausea/vomiting (86.3), arthraglia/myaglia (80.7%), and viral hepatitis (75.6%).
The least common manifestations among the study population were rash
(16.2%), hemorrhage (19.8%), and hepatosplenomegaly (27.4%). Stratification
by dengue infection status or effusion status did not find a significant difference
by each manifestation.

Table 4. Study Participants Manifestations by Dengue Infection Status and

Effusion Status in Hospital Ampang, Selangor, Malaysia 2010.
Infection Status

Effusion Status

Primary Secondary
N %
N
%

Absence Presence
N
%
N %

Total

Total Study Participants 41 20.8 156 79.2

N

%

115 58.4 82 41.6 197

100

Abdominal Pain

29 70.7 101 64.7

73 63.5 57 69.5 130

66.0

Arthraglia/Myaglia

31 75.6 128 82.1

91 79.1 68 82.9 159

80.7

Diarrhea

21 52.2

89 55.8

68 59.1 42 51.2 110

55.8

9 22.0

45 28.9

31 27.0 23 28.1

54

27.4

Hepatosplenomegaly
Nausea/Vomiting

36 87.8 134 85.9

99 86.1 71 86.6 170

86.3

Postural Giddiness

16 39.0

58 37.2

43 37.4 31 37.8

74

37.6

8 19.5

24 15.4

20 17.4 12 14.6

32

16.2

Retro-orbital/Headache

14 34.2

79 50.6

57 49.6 36 43.9
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47.2

Viral Hepatitis

29 70.7 120 76.9

88 76.5 61 74.4 149

75.6

Hemorrhage

10 24.4

29 18.6

-

-

-

-

39

19.8

Vascular Leakage

11 26.8

44 28.2

-

-

-

-

55

27.9

Rash
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Clinical Laboratory Results
The study population, on average, had an absolute monocyte count of
1.22 ± 0.94 (x10^9/L), platelet count of 56.9 ± 38.4 (x10^9/L), and a hematocrit of
41.6 ± 5.0 percent (Table 5).

Absolute monocyte count was observed to be

higher in secondary (1.35 ± 0.98) infections compared to primary (0.65 ± 0.37);
whereas, platelet count was observed to higher in primary (76.0 ± 38.7)
infections compared to secondary (51.9 ± 36.5). Stratification by dengue
infection status found a significant difference in absolute monocyte count (pvalue= <0.0001) and platelet count (p-value= 0.0002). No significant difference
was detected when the study population was stratified by effusion status for
absolute monocyte count, platelet count, or hematocrit. An independent sample
t-test was employed to determine significance.

Table 5. Clinical Laboratory Manifestations of Study Participants by Dengue Infection
Status and Effusion Status in Hospital Ampang, Selangor, Malaysia 2010.
Infection Status
Primary

Effusion Status

Secondary

^

Total

Absence

Presence

Avg. ± Std.

Avg. ± Std.

Avg. ± Std.

Absolute
0.66 ± 0.37 1.37 ± 0.98 ‡
Monocyte Count*

1.18 ± 0.90

1.28 ± 0.99

1.22 ± 0.94

Platelet Count * 75.6 ± 39.1 52.0 ± 36.8 ‡

55.6 ± 38.0

58.8 ± 39.1

56.9 ± 38.4

Hematocrit (%)

42.1 ± 4.8

41.0 ± 5.1

41.6 ± 5.0

Avg. ± Std. Avg. ± Std.

41.1 ± 5.3

41.7 ± 4.9

P-value: † <0.05; ‡ <0.01
* x10^9/liter
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Linear Regression Analysis
A multivariable linear regression analysis was used to determine the
association of venous absolute monocyte count with primary and secondary
dengue infection. A literature review provided the foundation for inclusion of the
risk factors gender, race, and age. A surrogate variable was assessed for
inclusion in the model for the known risk factors of infecting viral serotype,
socioeconomic status, and education. The surrogate variable used was distance
of participants’ residence from Hospital Ampang dichotomized by 12.5 km.
To determine if the surrogate variable was a potential risk factor for the
association stratification of the exposure and outcome by distance of participants’
residence from Hospital Ampang was completed. The outcome (independent
sample t-test, p-value = <0.001) and the exposure (chi-square, p-value=0.02)
were both significantly associated with distance of participants’ residence from
Hospital Ampang. As a result, distance of participants’ residence from Hospital
Ampang was considered a risk factor of the association and assessed for
inclusion in the regression model.
To assess the assumption that the data is normally distributed, graphical
analysis was used to plot the regression model predicted values against the
model residuals (Figure 32). Residuals are a measure of variation within the
dataset and are calculated by determining the difference between the observed
and expected values. A perfect fit of the model to the data would result in all
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residuals being zero; however, this is almost never observed. Under a
hypothetical normal distribution, a plot of the model predicted values against
model residuals will result in equal variance above and below zero. Graphical
analysis of the model predicted values against the model residuals of the dataset
under the base model displays a distribution that approaches normality. The
determination that the normality is approximated suggests the correct use of the
linear regression model for the analysis.

Figure 32. Scatter plot of residuals versus the predicted values of venous
absolute monocyte levels based on linear regression model with age as
categorical variable and without the distance variable.

The regression coefficient (estimate), coefficient standard error, and pvalues are presented in Table 6 for the above regression model. Regression
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coefficients are estimates of the independent contribution of each independent
variable to the prediction of the dependent variable, otherwise known as partial
correlation. Interpretation of the coefficients is first completed by observing the
signs (plus/minus). A positive coefficient delineates a positive relationship (as
the independent variable increases, so does the dependent variable) of the
independent variable with the dependent variable. Whereas, a negative
coefficient means the independent variable and dependent variable have a
negative relationship (when the independent variable increases, the dependent
variable decreases). A coefficient of zero infers no relationship between the
independent variable and dependent variable.
The value of the coefficient for each of the independent variables is a
measure of the effect of that particular variable has on the dependent variable.
In multivariable linear regression models, the coefficient is how much the
dependent variable is expected to increase when the independent variable is
increased by one, while holding all other independent variables constant.
Under the base model, dengue infection status (p-value= <0.0001) was
independently associated with venous absolute monocyte levels. All other
independent variables did not demonstrate a significant independent association
with venous absolute monocyte levels.

99

Table 6. Estimates from Linear Regression Model of
Venous Absolute Monocyte Levels during Defervescence
controlling for Dengue Infection Status, Age (categorical),
Gender, and Race.
Independent
Variable
Intercept
Infection Status
Age
Gender
Race

Estimate

Standard
Error

p-value

-0.19
0.72
-0.08
0.25
0.08

0.33
0.16
0.06
0.13
0.07

0.57
<0.0001
0.22
0.06
0.29

The coefficient of determination (R-squared) is a measure of the how
much of the data variance is explained by the linear model, or in other words,
how well the model fits the data. The coefficient of determination for the base
model is 0.127, meaning the model explains 12.7% of the variability in the
dataset.
The distance of the participants’ residence from Hospital Ampang was
added to the above model to assess any influence on the association of interest.
Graphical analysis using a plot of model predicted values against residuals
determined that under the model, the distribution approached normality
suggesting correct use of linear regression for the analysis (Figure 33).
A negative distance coefficient (β= -0.40 ± 0.16, p-value= 0.01) infers that
greater distance from Hospital Ampang is significantly associated with lower
monocyte levels (Table 7). Infection status has a positive coefficient (β= 0.72 ±
0.15, p-value= <0.0001), meaning that a secondary infection is significantly
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associated with increased monocyte count. A positive gender coefficient (β=
0.26 ± 0.13, p-value= 0.05) infers that male gender is significantly associated
with higher monocyte count. Age (β= -0.09 ± -0.06, p-value= 0.14) and race (β=
0.05 ± 0.07, p-value= 0.5) did not have a significant effect on the dependent
variable.
The addition of distance from the participants’ residence to Hospital
Ampang improved the linear fit of the model to the data, explaining 15% of the
dataset variability (r-squared = 0.15).

Figure 33. Scatter plot of residuals versus the predicted values of venous
absolute monocyte levels based on linear regression model with age as
categorical variable and including distance variable.
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Table 7. Estimates from Linear Regression Model of
Venous Absolute Monocyte Levels during Defervescence
controlling for Dengue Infection Status, Age (categorical),
Gender, Race, and Distance between Patient Residence
and Hospital Ampang.
Independent
Variable

Estimate

Standard
Error

P-value

Intercept

-0.05

0.33

0.89

Infection Status
Age
Gender
Race
Distance

0.72
-0.09
0.26
0.05
-0.40

0.15
-0.06
0.13
0.07
0.16

<0.0001
0.14
0.05
0.49
0.01

To determine if the age variable cut-points were masking or creating a true
association, the model was re-assessed with the age as a continuous variable. A
model not including the distance variable was initially fit. Graphical analysis
using a plot of model predicted values against residuals determined that under
the model, the distribution approached normality suggesting correct use of linear
regression for the analysis (Figure 34).
Infection status has a positive coefficient (β= 0.72 ± 0.16, p-value=
<0.0001), meaning that a secondary infection is significantly associated with
increased monocyte count (Table 8). Gender (β= 0.25 ± 0.13, p-value= 0.06),
age (β= -0.09 ± -0.06, p-value= 0.14), and race (β= 0.05 ± 0.07, p-value= 0.5) did
not have a significant effect on the dependent variable.
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Figure 34. Scatter plot of residuals versus the predicted values of venous
absolute monocyte levels based on linear regression model with age as
continuous variable and without distance variable.

Table 8. Estimates from Linear Regression Model of
Venous Absolute Monocyte Levels during Defervescence
controlling for Dengue Infection Status, Age (continuous),
Gender, and Race.
Independent
Variable
Intercept
Infection Status
Age
Gender
Race

Estimate

Standard
Error

p-value

-0.07
0.71
-0.01
0.25
0.08

0.34
0.15
0.01
0.13
0.07

0.84
<0.0001
0.08
0.06
0.24
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Assessing the age as a continuous variable did have an impact on the
model in that gender became non-significant and the r-square value was 0.13.
The distance of the participants’ residence from Hospital Ampang was
added to the above model to assess the variable’s influence on the association of
interest. Graphical analysis using a plot of model predicted values against
residuals determined that under the model, the distribution approached normality
suggesting correct use of linear regression for the analysis (Figure 35).

Figure 35. Scatter plot of residuals versus the predicted values of venous
absolute monocyte levels based on linear regression model with age as
continuous variable and including distance variable.
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A negative distance coefficient (β= -0.40 ± 0.06, p-value= 0.02) infers that
greater distance from Hospital Ampang is significantly associated with lower
monocyte levels (Table 7). Infection status has a positive coefficient (β= 0.71 ±
0.15, p-value= <0.0001), meaning that a secondary infection is significantly
associated with increased monocyte count. A positive gender coefficient (β=
0.26 ± 0.13, p-value= 0.04) infers that male gender is significantly associated
with higher monocyte count. Age (β= -0.01 ± -0.01, p-value= 0.06) and race (β=
0.06 ± 0.07, p-value= 0.4) did not have a significant effect on the dependent
variable.
The addition of distance from the participants’ residence to Hospital
Ampang improved the linear fit of the model to the data, explaining 16% of the
dataset variability (r-squared = 0.16).

Table 9. Estimates from Linear Regression Model of
Venous Absolute Monocyte Levels during Defervescence
controlling for Dengue Infection Status, Age (continuous),
Gender, Race, and Distance between Patient Residence
and Hospital Ampang.
Independent
Variable

Estimate

Standard
Error

P-value

Intercept

0.05

0.34

0.87

Infection Status
Age
Gender
Race
Distance

0.71
-0.01
0.26
0.06
-0.37

0.15
0.01
0.13
0.07
0.16

<0.0001
0.06
0.04
0.41
0.02
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Overall, including the distance surrogate variable and using age as a
continuous variable improved the linear fit of the model. For this investigation,
estimates from the model with age as a continuous variable and including
distance in the model will be accepted as the final model. However, future
investigations should strive to capture infecting viral serotype, socioeconomic
status, and education data to include in the model in place of the surrogate
variable.

Logistic Regression Analysis
A multivariable logistic regression model was used to determine the
association between venous absolute monocyte levels and effusion status
(presence or absence of hemorrhage/vascular leakage). A literature review
provided the foundation for inclusion of gender, race, age, and dengue infection
status (primary or secondary) in the initial model. Age was initially assessed as a
categorical variable. Assessment of distance of participants’ residence from
Hospital Ampang reveled an association with the exposure (independent sample
t-test, p-value = <0.001); however, no association was observed with the
outcome (chi-square, p-value= 0.35). While the criteria to be a confounder for
the association was not met, distance of participants’ residence from Hospital
Ampang was assessed in the analysis due to the need to control for other known
risk factors (infecting viral serotype, socioeconomic status, and education).
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Unlike linear regression models, logistic regression modeling does not
make assumptions about the distribution of the independent variables; however,
testing the fit of the model is important to avoid spurious results. To determine if
the fit of the base model was adequate, graphical analysis was used plotting
model Pearson residuals against estimated probability (Figure 36). If a model is
adequately fit, an approximately horizontal line will connect the end points in the
plot and have an intercept of zero. As a deviation from these criteria was
observed in the base model graphical analysis, this suggests the model is
inadequate to predict the outcome.

Figure 36. Scatter plot of Pearson residuals versus the predicted values of
venous absolute monocyte levels based on logistic regression model with age as
categorical variable.
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All independent variables under investigation did not display an
independent relationship with the dependent variable (absence and presence of
hemorrhage/vascular leakage) (Table 10).
The Hosmer-Lemshow test for goodness-of-fit is a chi-square statistic
testing whether or not the predicted model significantly differs from the observed
data; the desired outcome of the test is non-significance. The Hosmer-Lemshow
test for goodness-of-fit for the base model is non-significant (χ2= 0.26) meaning
that model accurately models the observed data.

Table 10. Estimates from Logistic Regression of Effusion Status Controlling for Venous
Absolute Monocyte Count, Age (categorical), Gender, Race, and Dengue Infection
Status.

Independent
Variable
Intercept
Monocyte
Age

Gender
Race
Race
Race
Infection Status

Reference

Estimate
-0.53
0.17
15-24
>45
-0.50
35-44
-0.41
25-34
-0.39
Male
0.47
Malay
Other
0.13
Indian
0.05
Chinese
0.16
0.08
Secondary

Hosmer and Lemeshow Goodness of fit = χ2 = 0.26
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Standard
Error
0.37
0.17
0.49
0.46
0.35
0.31
0.59
0.62
0.37
0.40

P-value
0.15
0.33
0.31
0.38
0.26
0.13
0.82
0.93
0.67
0.83

To determine if distance of participants’ residence from Hospital Ampang
affects the relationship of interest, the variable was added to the above model.
Graphical analysis of the logistic regression model plotting Pearson residuals
against estimated probability determined that the model was inadequate to
predict the outcome (Figure 37). All independent variables under investigation
did not display an independent relationship with the dependent variable (Table
11). The Hosmer-Lemshow test for goodness-of-fit for the base model is nonsignificant (χ2= 0.07) meaning that model accurately models the observed data.

Figure 37. Scatter plot of Pearson residuals versus the predicted values of
venous absolute monocyte levels based on logistic regression model with age as
categorical variable and including distance variable.
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Table 11. Estimates from Logistic Regression of Effusion Status Controlling for Venous
Absolute Monocyte Count, Age (categorical), Gender, Race, and Dengue Infection
Status.

Independent
Variable
Intercept
Monocyte
Age

Gender
Race
Race
Race
Infection Status
Distance

Reference

Estimate
-0.65
0.19
15-24
>45
-0.47
35-44
-0.39
25-34
-0.36
Male
0.48
Malay
Other
0.59
Indian
0.62
Chinese
0.37
Secondary
0.09
≤12.5km
0.28

Standard
Error
0.41
0.18
0.49
0.46
0.35
0.31
0.59
0.62
0.37
0.40
0.39

P-value
0.11
0.28
0.34
0.40
0.31
0.13
0.79
0.87
0.58
0.82
0.48

Hosmer and Lemeshow Goodness of fit = χ2 = 0.07

To determine if the age variable cut-points were masking or creating a
spurious association, the model was re-assessed with the age as a continuous
variable. A model without the distance variable was initially assessed. Graphical
analysis of the logistic regression model plotting Pearson residuals against
estimated probability determined that the model was inadequate to predict the
outcome (Figure 38). All independent variables under investigation did not
display an independent relationship with the dependent variable (Table 12). The
Hosmer-Lemshow test for goodness-of-fit for the base model is non-significant
(χ2= 0.64) meaning that model accurately models the observed data.
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Figure 38. Scatter plot of Pearson residuals versus the predicted values of
venous absolute monocyte levels based on logistic regression model with age as
continuous variable and without the distance variable.

Table 12. Estimates from Logistic Regression of Effusion Status Controlling for Venous
Absolute Monocyte Count, Age (continuous), Gender, Race, and Dengue Infection
Status.

Independent
Variable
Intercept
Monocyte
Age
Gender
Race
Race
Race
Infection Status

Reference

Estimate
-0.06
0.11
-0.02
Male
0.48
Malay
Other
0.10
Indian
0.08
Chinese
0.18
0.03
Secondary

Hosmer and Lemeshow Goodness of fit = χ2 = 0.64
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Standard
Error
0.53
0.17
0.01
0.31
0.58
0.62
0.36
0.38

P-value
0.91
0.52
0.13
0.12
0.87
0.90
0.62
0.95

To determine if distance of participants’ residence from Hospital Ampang
affects the relationship of interest, the variable was added to the above model.
Graphical analysis of the logistic regression model plotting Pearson residuals
against estimated probability determined that the model was inadequate to
predict the outcome (Figure 39). All independent variables under investigation
did not display an independent relationship with the dependent variable (Table
11). The Hosmer-Lemshow test for goodness-of-fit for the model is nonsignificant (χ2= 0.59) meaning that model accurately models the observed data.

Figure 39. Scatter plot of Pearson residuals versus the predicted values of
venous absolute monocyte levels based on logistic regression model with age as
continuous variable and including distance variable.
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Table 13. Estimates from Logistic Regression of Effusion Status Controlling for Venous
Absolute Monocyte Count, Age (continuous), Gender, Race, Dengue Infection Status,
and Distance between Patient Residence and Hospital Ampang.
Independent
Variable
Intercept
Monocyte
Age
Gender
Race
Race
Race
Infection Status
Distance

Reference
Estimate
-0.17
0.13
-0.02
Male
0.49
Malay
Other
0.12
Indian
0.11
Chinese
0.22
0.04
Secondary
≤12.5km
0.26

Standard
Error
0.56
0.17
0.01
0.31
0.58
0.62
0.36
0.38
0.39

P-value
0.76
0.46
0.14
0.12
0.84
0.85
0.54
0.92
0.50

Hosmer and Lemeshow Goodness of fit = χ2 = 0.59

Overall, the inability of the model building process to produce significant
findings speaks to the complex biological nature of dengue disease. No
acceptable final model was produced in this research for the secondary objective
as all models were found inadequate to predict the outcome. As researchers
continue to unravel the complex dengue disease biological pathway future
attempts to model disease outcome by including new variables might have better
success.
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DISCUSSION
Prior to the discussion of the study results, an assertion of the internal
validity of the study is necessary. Internal validity of a study is based around the
premise of a high degree of precision in the association under investigation
(Oleckno, 2002). If a study does not maintain internal validity, external validity
cannot be achieved. In epidemiologic studies, three factors can affect internal
validity: chance, bias, and confounding.
Chance, also known as random error, can be separated into two primary
sources: measurement and sampling error. Measurement error occurs during
the measurement of individual values for study analysis and is avoided through
diligent study planning. The two sources of data for the study were clinical data
from Hospital Ampang and laboratory data from the Medical Microbiology
Laboratory of Professor Dr. Shamala Devi. All clinical data from Hospital
Ampang was collected from the hospital electronic database. Only trained
medical professionals have access and can enter values into the hospital
electronic database, providing a high degree of certainty about the
measurements. Both laboratories of Hospital Ampang and Professor Dr.
Shamala Devi’s employed the use of standardized controls. These controls
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allowed the trained laboratory personnel to determine if the assay was working
properly, reducing measurement error.
Sampling error is the “variation that can result when using sampling
statistics to estimate population parameters” (Oleckno, 2002, p.152). Sampling
error is reduced by having a large enough study population to detect the
association of interest above any random variation. While one may haphazardly
overestimate the study population needed, an efficient use of both time and
limited financial resources is achieved through a priori sample size calculation.
As the study was subset within another study, an a priori sample size
calculation was not feasible. A retrospective power calculation conducted based
on literature estimates ensures that if an association did exist, it could be detect
above variations within sampling. The retrospective power calculation
determined that the study had a power of 0.87, meaning that if an association
exists, it will be detected 87% of the time. With studies typically aiming for a
power of 0.80 (Oleckno, 2002), the study exceeds standards set for study power.
Bias is “nonrandom error in the design, conduct, or analysis” of an
epidemiological study (Oleckno, 2002, p.125) and can be classified as selection
or measurement. As bias cannot be addressed after the data has been
collected, careful study design planning is necessary to avoid spurious results.
Selection bias is the nonrandom error by which study participants are
selected or retained (Oleckno, 2002). To avoid selection bias, collection of
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subjects must be conducted so that the study population represents the target
population, subject loses are kept to a minimum, and comparison groups within
the study are similar except for the variables being investigated (Oleckno, 2002).
Data on the target population of the study were not available; however,
summary statistics on the approximate (in- and out-patient) source population
were obtained for the 2010 calendar year. No significant difference was detected
between the approximate source population, source study population, and study
population by age, gender, and race.
Successful participant recruitment and reduction of loss to follow-up is
critical to minimizing bias within the study. With participation rate slightly above
the standard cut-off of 20% (Galea & Tracy, 2007) and retention rate of 96.2%,
the source study design was successfully executed, reducing a major source of
bias. To confirm this statement, chi-squared tests for independence were
conducted between the source study population and the population of individuals
who refused to participate by gender, race, age, and distance between residence
and Hospital Ampang; no significant difference was observed. The finding of no
difference between populations infers that recruitment bias had negligible impact
on the study, meaning patients decided to participate in the study in a nonsystematic way.
Ideally, a study will recruit a population which does not significantly differ
by risk factors so that the association of interest can be correctly assessed.
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When the study population was stratified by the exposure of interest, primary and
secondary dengue infection, there was no significant difference detected by
gender, race, or distance between residence and Hospital Ampang. However, a
significant difference was detected between primary and secondary infections
among those aged 45 years and older. This finding is understandable in that as
a person ages they will have been at increased risk for multiple dengue infections
compared to an individual of younger age while living in a dengue endemic
environment. Also, as an individual ages their immune system is less capable of
handling disease stress necessitating more medical intervention compared to
young populations. The use of multivariable analysis will allow for consideration
of this difference to correctly assess the association of interest. The above
findings provide assurance that negligible amounts of selection bias were
introduced into the study as far as can be detected.
Measurement bias is the “nonrandom error in classifying subjects with
regard to exposure or outcome status” that may result from inaccurate
measurements (Oleckno, 2002, p.144). As both the exposure and outcome of
interest were determined through the use of standardized laboratory assays, both
of which employed controls, the risk for differential misclassification is minimal. If
the assay standardized controls were not met, enough of the venous serum
sample remained to repeat the assay several times until control verification was
met.
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Confounding is nonrandom error by the distortion of the association of
interest by an incidental factor. A confounder, termed risk factor in epidemiology,
must be 1) associated with the exposure; 2) an independent risk factor for the
outcome; 3) must not be an intermediate variable on the causal pathway; and 4)
must be present in different degrees between study groups (Oleckno, 2002).
Confounding can be controlled during the planning phase of the study through
restriction, matching, and/or randomization. Multivariable analysis during the
analysis phase of the study can control for confounding effects only if they were
measured during the study (Oleckno, 2002).
Potential risk factors of the primary relationship of interest include gender,
race, and age, which were determined through the literature review. Knowledge
of the study location suggested distance between patient residence and Hospital
Ampang might be a potential risk factor. Stratification of the exposure and
outcome by the risk factor allowed for associations to be assessed. As there was
an association of the risk factor with the exposure and outcome, distance
between the participants residence with Hospital Ampang was classified as a
potential risk factor for the primary relationship of interest. All risk factors were
taken into account in the multivariable analysis.
Having successfully addressed, as far as can be determined, the potential
effects of chance, bias, and confounding on the study, the study internal validity
has been maintained. The following presents a discussion of the study
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population disease duration, co-morbidities, manifestations, and clinical
laboratory results with comparison to findings from the literature.
The duration of time from onset of illness to hospital admission and length
of hospitalization was similar across the source study and study populations.
From the literature, a 2008 cross-sectional study among 236 dengue patients
from two hospitals in Federal Territory of Kuala Lumpur and State of Selangor,
Malaysia, found the average length of time from onset of illness to admission to
be 4.9 days (Ang, Rohani, & Look, 2010). A separate prospective cohort study of
77 dengue hospitalized adults in Kuala Lumpur, Malaysia, from December 2004
to December 2005, observed the average length of hospitalization to be 2.4 ± 5.3
days (Lum et al., 2008). While the study population and literature findings had
similar durations between onset of illness and admission, the length of
hospitalization was longer in the study population compared to the literature. The
dissimilar findings might be due to differences in severity of dengue disease
within the populations and/or standard of care between hospitals. There are no
exact criteria for patient discharge and is highly dependent on overall patient
health. Further research would be need to elucidate why discharge time periods
differ.
The low prevalence of co-morbidities (7.6%) within the study population is
potentially reflective of the relative young overall age of study participants (31.2 ±
11.7 years). Comparable proportions of co-morbidities in the study population,
when stratified by dengue infection and effusion status, indicates a comparatively
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homogenous study population with respect to diagnosed chronic diseases. From
the literature, a study of 120 dengue patients aged 15 to 73 years in Singapore
from 2000-2005 indicated a similar prevalence of co-morbidities within the study
population (10%) (Lye, Chan, Lee, & Leo, 2008). The low prevalence of comorbidities in both the study population and findings from literature, allow for the
observation that dengue is affecting a mostly healthy population and inference
that co-morbidities might not have a significant role in the development of severe
dengue complications. While not observed in the study population, comorbidities that have been associated with adverse dengue outcomes include
obesity, diabetes mellitus, hypertension and chronic heart diseases (Farrar et al.,
2007).
Dengue disease commonly manifests with rash, nausea/vomiting, and
arthraglia/myaglia (WHO/TDR, 2009). Study participants were observed in high
proportions to have nausea/vomiting and arthraglia/myaglia; however, rash was
the least observed manifestation. The low presence of rash within the study
population may be due to the overall late admission (~day 4 of illness) to Hospital
Ampang by which time rash may have resolved. Further dissimilarities between
the study population and literature from Kuala Lumpur (Lum et al., 2008), include
the low proportion of study participants manifesting with pleural effusion,
bleeding, dizziness, and abdominal pain. A review of dengue literature outside
Malaysia has found populations with similar proportional manifestations to that of
the study population (Thomas et al., 2010; Kumar et al., 2010). The differences
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and similarities in manifestations among the study population compared to
findings in the literature, illustrates the high degree of variation in dengue disease
clinical manifestations. Clinicians must be aware of the wide-range of
manifestations that can be observed during dengue disease. Using the new
dengue classification criteria proposed by WHO in 2009, all study participants
were capable of being classified. This finding supports the use of new
classification criteria; however, future studies are needed to ensure continued
flexibility of the classification criteria, especially as populations in dengue
endemic counties begin to age.
Analysis of each manifestation by both primary & secondary dengue
infection and absence & presence of hemorrhage/vascular leakage did not
observe a significant difference. These findings are not unexpected as the study
population is comprised of patients who were admitted to Hospital Ampang for
severe dengue complications. What is striking is the similarity between primary
and secondary for presence of hemorrhage and vascular leakage. Commonly,
hemorrhage and vascular leakage are thought of as complications only observed
in heterotypic secondary dengue infections. The findings are a reminder that
severe dengue complications are not just manifestations that occur in secondary
heterotypic dengue infections. However, the similar observed proportions of
hemorrhage and vascular leakage in the study population are not representative
of those experienced in the general population, as the study was designed to
focus on those individuals who develop severe complications. Among the
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general population, the majority of primary dengue infections will not develop
severe complications, whereas those experiencing a secondary infection will be
at an increased risk for severe complications.
The wide range of manifestations in dengue disease highlights the need
for a highly flexible dengue diagnostic scheme to clinically classify dengue
patients. A recent review in 18 countries shows that the 2009 dengue diagnostic
scheme could classify all but 1.7% of study participants; whereas the 1997
dengue diagnostic classification criteria could not classify 13.7% of study
participants (Barniol et al., 2011). There is still a need for further research and
possible re-structuring of the dengue classification criteria to ensure that all
individuals who are laboratory diagnosed with dengue can be readily diagnosed.
A decreasing platelet count and concurrent increasing hematocrit, are
early clinical warning signs of potentially severe dengue complications
(WHO/TDR, 2009). The study population mean hematocrit remained within the
normal range of 36.0-48.0%, most likely as a result of the immediate and
attentive rehydration therapy administered by the Hospital Ampang medical staff.
As more medical facilities increase their rehydration therapy capabilities,
hematocrit may not remain a commonly observed indicator of potential severe
dengue complications. Platelet count of the study population was well below the
150-400 (x10^9/L) platelet count normal range. As the majority of study patients
were even below the 100 (x10^9) platelet count threshold, this gives more
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evidence for the appropriate lowering of the platelet count dengue criterion
(Rigau-Perez, 2006).
The study population average absolute monocyte count was above the
normal range of 0.1 - 0.8 (x10^9/L). However, when the study population was
stratified by infection status, the primary infection population average absolute
monocyte count reduced back into the normal range, whereas the secondary
infection population remained above the normal range. The difference between
the primary and secondary infection status absolute monocyte counts was found
to be significant. The literature review did not find a study which assessed a
similar research relationship. To fully analyze this association, potential risk
factors of the association were assessed with multivariable linear regression
analysis.
An initial linear regression model was constructed with dependent variable
absolute monocyte count and independent variables infection status (primary or
secondary), race, age, and gender. Assumptions of the methodology were
graphically assessed and fit of the model determined. Distance of the
participants’ residence from Hospital Ampang was added to the initial model to
determine if the variable influenced the association. In the initial model, the age
variable was assessed as categorical variable with cut-points used from the
literature; however, it was necessary to determine if categorizing the age variable
was masking or creating artificial findings. The age variable was run in the initial
model as a continuous variable. The distance variable was again added to the
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initial model, with a continuous age variable, for reassessment of the influence on
the association. Comparing the assumptions of the methodology and fit of the
model between the four models, it was determined that the final model would be
the model using a continuous age variable and including the distance variable as
the final model (Table 9).
The final model finding that secondary dengue infection significantly
increases absolute monocyte during defervescence is presumably a novel
contribution to the dengue literature. Specifically, a secondary dengue infection
increases the venous absolute monocyte count by 0.71±0.15 (x10^9/L)
compared to a primary dengue infection, while holding all other independent risk
factors constant. Among all independent variables considered in the model,
infection status had the largest effect size and was most significant for the
association.
As the normal range of venous absolute monocyte count in adults is 0.1 to
0.8 (x10^9/L), the average value observed in those with primary dengue infection
is within these normal bounds; however, secondary dengue infections have an
average abnormal elevated count. The severe dengue biological pathway
hypotheses of antibody-independent enhancement and memory T-cell
reactivation, revolve around the central idea that a previous dengue infection
alters the immune response. As a result of the immune system alteration, during
a secondary heterotypic dengue infection, severe dengue complications occur.
The study does not validate either severe dengue hypothesis, but does provide
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further evidence that monocytes are more abundant in a secondary heterotypic
dengue immune response compared to a primary dengue immune response.
Increased monocyte count is commonly observed in inflammatory disorders
(Moore & Tabas, 2011), which supports the biological pathway of severe dengue
complications potentially being caused by proinflammatory cytokines released by
monocytes. This information will prove valuable in formulating further study
hypotheses that may eventually lead to a comprehensive understanding of the
severe dengue biological pathway.
Furthermore, the study presents evidence to that while race and age do
not significantly influence the relationship better absolute monocyte count and
primary & secondary dengue infection, gender and distance of residence from
Hospital Ampang do modify the association.
The literature has found an increased risk of severe dengue in children
compared to adults and suggests stress from the dengue disease on
undeveloped capillaries to be a potential cause of the finding. The study has
observed a -0.01 ± 0.01 (x10^9/L) (p-value= 0.06) decrease in absolute
monocyte count for each year a person ages, holding all other variables
constant. This finding, while non-significant, still remains important as it suggests
another potential influence on the association for increased risk in younger aged
individuals. The immune system, while typically vibrant and strong in youth,
weakens with age. A youthful immune system may lead to an unnecessarily
strong immune response causing damage to the capillaries.
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The finding also raises the question about what happens in old age when
the immune system has weakened so much that it cannot handle the dengue
infection. Few studies have investigated the effects of dengue on the elderly.
More studies should be conducted on the elderly demographic as dengue is
currently spreading to non-endemic regions where the vast majority of the elderly
population has not experienced a dengue infection before.
Literature has suggested that genetics (i.e. HLA types) may influence the
outcome of a dengue infection. As genetic analysis was not available for
inclusion in the study, race was used as a surrogate variable. The analysis
determined that race had negligible effect on the primary association of interest
(0.06 ± 0.07 x10^9/L, p-value = 0.41), suggesting that race is an imperfect
surrogate variable for genetic variation within the study population. Research is
needed to identify and confirm genes that increase the risk for severe dengue
complications for proper consideration of the potential risk factor.
Blood profiles have differing normal ranges for males and females on
many components (e.g. hematocrit & hemoglobin); however, no such difference
in normal range by gender exists for absolute monocyte count. Among the study
population, an individual of male gender increases the venous absolute
monocyte count by 0.26 ± 0.13 (x10^9/L) (p-value=0.04) compared to an
individual of female gender, while holding all other independent risk factors
constant. The significant influence of male gender on absolute monocyte count,
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suggests physiological and/or genetic differences may play a role in the immune
response.
From knowledge of the study site, a concern developed that since some
patients were being transferred to Hospital Ampang, they would differ from those
individuals who go to Hospital Ampang because it was the closest location for
medical treatment. All four dengue serotypes are currently co-circulating within
Malaysia. Individuals who were being transferred to Hospital Ampang may have
contracted a different serotype or strain of dengue virus, which may cause a
different immunological response than the predominant virus being circulated
near Hospital Ampang. As dengue viremia typically drops below detectable
levels by Day 4 of symptomatic illness, and study participants were admitted on
average to Hospital Ampang on Day 4.07 ± 1.55 of symptomatic illness, most
study participants infecting dengue serotype could not be determined. Only 17 of
197 study participant’s dengue infecting serotype were determined through PCR
analysis.
Education and socioeconomic status are risk factors for increased
incidence of dengue infection. Individuals with higher education levels show
protection against dengue infection for several potential reasons. First, they are
more likely to have been taught the dangers of dengue and how to prevent
infection. Secondly, individuals with higher education tend to earn more which
allows them to move to a residence that may provide better protection from the
dengue vectors. Lastly, with increased socioeconomic status a family can afford
127

to take preventative steps to reduce vector breeding sites and can afford
privatized medical care that may have better individualized care.
As information on the above factors was not available or incomplete for
the entire study population, the average distance (12.5 km) between Hospital
Ampang and other public hospitals was used as a generalized surrogate
variable. This cut-point was arrived at by averaging the distance between
Hospital Ampang and the five nearest public hospitals. This cut-point provides a
generalized boundary by which to identify those individuals who travel a further
distance to receive care at Hospital Ampang, and those individuals who are
travelling to the nearest public hospital.
Among the study population, an individual with a residence of greater than
12.5 km from Hospital Ampang is found to decrease the venous absolute
monocyte count 0.37 ± 0.16 (x10^9/L) compared to an individual with a residence
equal or less than 12.5 km from Hospital Ampang, while holding all other
independent risk factors constant. The significant finding (p-value= 0.02)
suggests that the study population differed on one of the above mentioned
factors. Future studies should include these three risk factors to better consider
confounding effects of the relationship of interest.
The analysis of the relationship between absolute monocyte count and
primary & secondary dengue infection status considering the effects of
independent risk factors has answered the second primary aim. However, after
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reviewing the results of the study, more questions have been raised.
Hypothetically, if the study results had observed an elevated absolute monocyte
count both in primary and secondary dengue infections, one may hypothesize
that the elevated monocyte levels cause an increased release of proinflammatory
cytokines. The elevated levels of cytokines could then cause the study
participant’s severe dengue manifestations. While all study participants had
severe dengue complications, the absolute monocyte count was significantly
increased in secondary dengue infections compared to primary infections. The
foremost question that comes out of this finding is what is the biological pathway
behind primary dengue infection development of severe dengue complications?
As dengue virus can infect monocytes, and monocytes have been shown to
release proinflammatory cytokines, normal levels of monocytes in primary
dengue infections does not sequentially lead to severe complication development
with current dengue knowledge. So, are there multiple biological pathways by
which severe dengue manifests? Even with a lower number of monocytes, do
severe cases of dengue release similar levels of cytokines? Do monocytes in
primary and secondary dengue infection cases release the same type of
cytokines? These are the questions which researchers may be able to
immediately answer to further clarify the severe dengue biological pathway.
To investigate the secondary aim of the study, logistic regression analysis
was used to investigate the relationship of presence and absence of
hemorrhage/vascular leakage with absolute monocyte count considering the
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potential confounding effects of independent risk factors. The analysis included
assessing the distance of study participant’s residence from Hospital Ampang
and the age variable as both categorical and continuous. Assumptions of the
methodology were graphically assessed and fit of the model determined.
The logistic regression analysis did not produce an acceptable model to
explain the observed relationship in the data and no significant or meaningful
non-significant associations were established. While disappointing, the outcome
is not entirely unexpected with the variation in the literature findings and complex
nature of the dengue immune response. Future studies need to employ clear
hypotheses that pick apart the biological pathway with well designed studies.
After the a comprehensive severe dengue biological pathway has been
hypothesized, a large study that has ample power to detect the association of
interest maybe employed in a similar manner as the above analysis to determine
the effect of each independent risk factor.

Limitations
The primary objective of the study was to assess the relationship of
absolute monocyte count with primary and secondary dengue infection status.
The study findings have restricted inference due to several limitations.
The literature review did not find another published article examining the
study’s hypothesis, potentially making this a novel investigation. As the study
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was conducted in a single population in Malaysia, further research is necessary
to assess applicability of the study findings to other populations within and
outside of Malaysia.
Dengue infection is unpredictable and has a wide range of clinical
manifestations, from asymptomatic to life threatening complications. The study
targeted individuals aged 15 years and above who had symptoms severe enough
to require hospitalization. Therefore, study findings can only be inferred to this
population as it does not consider the population of individuals who develop mild
or asymptomatic dengue disease or are aged less than 15 years.
The Malaysian healthcare system is two tiered: public and private.
Conducting the study in a public hospital necessitates special consideration
when determining to which populations the study findings can be inferred. Cost
of care between public and private hospitals will undoubtedly dichotomize
populations served. Also, differences in standard of care or medical capabilities
in equipment or personnel may affect disease outcome.
There are opposing observations on whether or not SES and education
are risk factors for dengue incidence, which suggests published results may be
population dependent (Waterman et al., 1985; Spiegel et al. 2007; Da Gloria
Teixeira et al., 2002). Furthermore, nutritional status, which is highly dependent
on SES, has conflicting findings for the presence of decreased risk for severe
dengue among malnourished populations (Kalayanarooj & Nimmannitya, 2005;
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Maron et al., 2010; Thisyakorn & Nimmannitya, 1993). Consequently, the
inability to include SES and education in the study analysis, as the data was not
available in hospital records from which study data was collected, may limit the
inference of study findings to the general population.
Susceptibility for the development of severe dengue is largely dependent
on the host immune response. The inclusion of the risk factors race, gender, and
age in the study analysis will allow for consideration of biological differences
between study participants. Inconsequentially, having not included education or
SES will not have an effect on the internal validity of the study. Even with the
discussed limitations, the study still has significant potential to contribute to
knowledge of dengue disease.

Conclusions
The antibody-dependent enhancement and reactivation of memory T-cell
hypotheses are currently the most comprehensive biological pathway models in
the development of severe dengue manifestations. Under both hypotheses, a
primary dengue infection modifies immunological components, which, during a
secondary heterotypic infection, cause an excessive immune response resulting
in disease complications. The dengue literature has provided evidence that
monocytes are involved in the development of severe dengue; however, lacking
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was analysis of whether monocyte involvement differed based on previous
exposure to the dengue virus.
The study has observed a differential association of venous absolute
monocyte count with primary and secondary dengue infection during
defervescence. Overall, absolute monocyte count is significantly increased in
secondary compared to primary dengue infections. The association is
increasingly modified by male gender and a distance of less than 12.5 km of the
participant residence from Hospital Ampang. Additionally, no significant
association was observed between absolute monocyte count with absence and
presence of hemorrhage/vascular leakage.
The study epidemiological evidence that the monocyte immune response
is enhanced in secondary infection compared to primary infection provides
further support of both the involvement of antibody-dependent enhancement and
reactivation of memory T-cell hypotheses in the development of severe dengue.
The inability to detect a relationship of absolute monocyte count with absence
and presence of hemorrhage/vascular leakage is not entirely unexpected and
speaks to the complex multifactorial immune response resultant of a dengue
infection.
Currently, phase three clinical trials are ongoing for a dengue vaccine;
however, even with a potential future licensed dengue vaccine, coverage of the
entire human population at risk is years into the future, if ever. Dengue has
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shown to be able to be passed through vertical transmission within the vectors,
meaning dengue, even in a population with complete vaccine coverage, will
survive and remain a threat to future unvaccinated generations.
Beyond the development of an easily administrable and safe tetravalent
dengue vaccine, the over-riding challenge of the dengue research community is
to understand the severe dengue biological pathway. A comprehensive
understanding of the biological pathway will greatly aid researchers in developing
medical interventions to lessen or prevent severe dengue complications after a
dengue susceptible has been infected. Having a tetravalent dengue vaccine and
specific medicines to reduce the risk of severe complications will provide public
health professionals the necessary tools to effectively reduce the burden of
dengue on the human population.
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APPENDICES
Appendix A: Epidemiological Transitions: The Human and Disease
Relationship
An understanding of epidemiological transitions during human history will
provide a foundation to the reader upon which to grasp and interpret the
empirical evidence discerned in this study. The intended objective of the
following section is to present a historic overview of the relationship between
humans and disease as a backdrop for further, more in depth analysis of dengue
epidemiology. The framework for the following discussion will use a theory
expansion presented by Barrett and colleagues of Abdel Omran’s originally
presented theory of “epidemiological transition” or “health transition” (Omran,
1971; Barrett, Kuzawa, McDade, & Armelagos, 1998).
The epidemiology transition theory concentrates on major human
morbidity and mortality patterns along with the “demographic, economic and
sociologic determinants and consequences” (Omran, 1971). Barrett and
colleagues (1998) identify three major epidemiological transitions during the
period of time from our common hominoid ancestors until today, which
incorporate many of Omran’s original findings. To describe the period of time
before the first epidemiological transition, Omran (1971) coined the phrase: “The
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Age of Pestilence and Famine.” This period of time began with the first hominoid
ancestors on the African savanna lasting until the late-17th century.
Characterizing “The Age of Pestilence and Famine” was a high mortality and
birth rate. Population patterns were defined by epidemics and famine while
remaining low in total population, as compared with the 20th & 21st centuries
(Figure 1A, Phase 1).

Figure 1A. Epidemiological transitions (UN, 2009a) edited.

“The Age of Pestilence and Famine” can be analyzed by conceptualizing a
dichotomous break along food collection methods: foraging and agriculture.
From the interpretations of archeologists and anthropologists, modern human
pre-historic ancestors on the African savanna are thought to have lived in small
nomadic tribes who foraged for food (Burnet & White, 1962). Population
dynamics would have not favored disease organisms of low pathogenicity or high
virulence as the organism would have not encountered a large enough
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population to sustain transmission. Diseases which were likely to affect the early
hominoids were enteric bacterium, transferred by the oral-fecal route, and head
and body lice (Cockburn, 1971, as cited in Barrett et al., 1998). As early
hominids increased tool usage and dispersed throughout Europe, Asia and
eventually colonizing much of the globe, they would have disturbed different
ecological niches increasing their risk for contracting novel diseases. Sustained
transmission of an emerging diseases resulting in an endemic nature in the
hominoid population would have remained low during this period of foraging as
populations would have remained below sustainable disease thresholds of
transmission (Barrett et al., 1998).
Approximately 10,000 years ago, the early nomadic tribes began to
establish permanent settlements and no longer used foraging as a primary
method for food collection, turning to agriculture (Barrett et al., 1998). The
transition to food cultivation had no significant effect on the high mortality and
birth rates, however; they allowed for the development of slightly larger
populations which introduced a number of new disease threats. An enlarged,
sessile population allowed for increased contact between individuals and
accumulation of waste (Barrett et al., 1998). Furthermore, increased population
densities would have allowed viral infections such as measles, smallpox and
respiratory infections, along with vector-borne diseases (e.g. plague and typhus)
to thrive. Cholera epidemics would have occurred with accumulated waste
(Knapp, 1989). During this period, zoonotic diseases (e.g. tuberculosis, anthrax
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and Q fever) would have emerged due to increased contact with domesticated
animals (Polgar, 1964, as cited in Barrett et al., 1998)
The first accounts on the origin of disease come from documents written
by the great ancient civilizations of modern day Egypt, India, and China. Disease
was generally thought of an external affliction caused either by the wrath of a well
intentioned god(s) who the individual had upset, or the hex from an evil demon.
This supernatural stance on the origin of disease was in turn treated with highly
superstitious remedies, many of which did more harm than good to the afflicted
(Nunn, 2002). Supernatural disease origin has not faded with antiquity but
remains in present times, most observably in the practices of shamanism (de
Schweinitz, 2010). Not until approximately 400 Before Common Era (BCE) in
Greece, did a shift in philosophy towards a natural or internal origin of disease
occur. Hippocrates, known as the “Father of Modern Medicine,” has been given
credit for this shift in disease philosophy, among many other significant
contributions, forming a foundation for medical advancement (Jouanna, 1999).
By the 14th century of the Common Era (CE), humans had formed
regional populations, interacting through trading routes over land and on the high
seas (McNeill, 1976). While trade spurred economies, within the trading vessels
tradesmen and vector alike carried diseases to new populations. Originating in
China, the plague or Black Death travelled across the Asian continent and then
throughout Europe (Wade, 2010). Plague, caused by the bacterium Yersinia
pestis, is transmitted to humans through the bite of a flea, direct contact or
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indirect droplet inhalation. The Black Death peaked during 1348-1350CE and is
estimated to have killed 1/3 of the European population (Ziegler, 1969). The
increasingly crowded and unsanitary conditions in combination with poor
nutritional diets brought destructive epidemics throughout the remainder of the
“Age of Pestilence and Famine” (McNeill, 1976).
The first major historical epidemiological transition began in the late
seventeenth century in Europe which entered “The Age of Receding Pandemics”
(Omran, 1971). As the name suggests, pandemics, while not absent, become
less devastating as dietary, sanitation and hygiene efforts increase. Defining the
era is a drastic drop in mortality rate and increase in life-expectancy which, when
combined with a very high birth rate, resulted in a substantial natural increase in
the total population (Figure 1A, Phase 2) (Omran, 1971). While increases in
basic standards of living aided in the decreased mortality rate, without the
intellectual contributions of John Snow, Louis Pateur and Robert Koch,
improvements in human health may not have been sustained.
John Snow, an English physician, is considered to be one of the fathers of
epidemiology for his work on a cholera outbreak in Soho, England (Hempel,
2007). A skeptic of the miasma theory, which stated that diseases where caused
by “bad air,” Snow used mapping of cholera cases and statistical analysis to
show an association with the outbreak point source, a water pump (Hempel,
2007). Refuting “bad air,” the disease origin dogma of the day, John Snow
provided bases for further disease origin investigations.
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Not until Louis Pastuer’s experiment to refute spontaneous generation and
subsequent statement of the Germ Theory of Disease during the 1860’s, did the
true causal relationship between disease and humans begin to become evident
(Metchnikoff, 1971). The Germ Theory is based on the idea that disease is
caused by the invasion of the body by microorganisms. In 1880, Robert Koch
empirically validated Louis Pastuer’s Germ Theory and proposed his own
postulates on the matter of disease origin (Metchnikoff, 1971). Still used today,
Koch’s Postulates are a set of four criteria used to empirically determine if a
microorganism is the causal agent for a disease.
Late into the 19th century and beginning of the 20th century, medical
science was rapidly advancing the understanding of disease and beginning to
produce effective primary prevention in the form of vaccines. Edward Jenner is
given credit for having created the first vaccine against the smallpox virus
through the method of variolation of cowpox scabs in 1796 Current Era (CE)
(Allen, 2007). After a gap of almost a century, vaccine development progressed
to address rabies (1884), cholera and typhoid (1896), plague (1897), and
pertussis (1915) (Link, 2005). During this time period, medical science was
beginning to feel they could solve infectious diseases; however, with the world at
war the influenza pandemic of 1918 took the world and field of science by
surprise. Unlike most infectious diseases which target the very young, elderly
and immunocompromised, pandemic influenza of 1918 targeted healthy young
adults (Kupperburg, 2008). Researchers of the day rushed to develop a vaccine
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for influenza. Unfortunately, these vaccine attempts would prove unsuccessful
dampened by the initial hypothesis that the pandemic was caused by a bacterium
(Kupperburg, 2008).
Although the influenza pandemic of 1918 had exposed the medical and
scientific communities for their limited prevention capabilities, following World
War II North America was soon undergoing a second epidemiological transition.
The transition was as a result in a surge of scientific and public health triumphs,
including: the eradication of polio, improved sanitation requirements, federal
oversight to further protect consumables in America (e.g. Federal Food, Drug,
and Cosmetic Act, 1938, USA) and the continued discovery of new more
powerful antibiotics (Boሷttcher, 1964).
”The Age of Degenerative and Man-Made Diseases”, is the second
epidemiologic transition defined by a constant low mortality rate and decreasing
birth rate (Omran, 1971). The decreasing birth and infant mortality rates are
generally a result of increased access to healthcare and education for women
and children (Newland, 1981). During this third transition period, the total
population expands rapidly in the beginning, but as the birthrate drops, the
population growth rate slows (Figure 1A, Phase 3). Sustained public health
efforts see a continued drop in infectious disease mortality, combined with the
increased lifespan, results in chronic diseases, for the first time, becoming the
leading cause of mortality (Omran, 1971). Chronic diseases with high
prevalence in this stage include cancer, diabetes, coronary artery disease and
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chronic obstructive pulmonary disorder (Kaplan & Keil, 1993). These diseases
have a multitude of risk factors, including tobacco, alcohol, human made
environment pollution (i.e. air, water & noise), diet and decreased exercise.
The transition between the receding pandemic and man-made disease
eras is not typically as abrupt as written in this thesis. Low-income countries may
not have been able to afford to invest enough in their public health infrastructure
to rid their country of infectious disease epidemics. At the same time,
globalization (e.g. increased pollution, availability of tobacco and alcohol) and the
westernization of the diet (i.e. increased sugar, salt and fat [especially from
animals] intake) increase the burden of chronic diseases on the population. This
double burden is evident by the WHO reporting that 80% of chronic disease
deaths occur in low and middle income nations (WHO, 2005). There is a
continued need to address both chronic and infectious disease problems
simultaneously.
Snowden (2008) has deemed the period since the discovery of antibiotics
in the 1940’s: “The Age of Hubris.” While the tenth Surgeon General of the
United States has been incorrectly quoted as saying it was “time to close the
books on infectious diseases” (Spellberg, 2008), this attitude was in fact the
overwhelming mood of world leaders of the day demonstrated by the US
Secretary of State George Marshall declaring in 1948 that the world had the
ability to rid itself of infectious diseases (Lederberg, 1997; Snowden, 2008). Also
during this period, Aidan Cockburn, an epidemiologist at John Hopkins University
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and WHO advisor, even went as far as to give a timetable for complete infectious
disease eradication: achieved by “2060” (Cockburn, 1963, as cited in Barrett et
al., 1998).
The feeling of inevitable conquest over infectious diseases was being
fueled by the post-World War II social uplift in earnings, education, diet and
sanitation, food production, the discovery of the “magic bullet” for malaria quinine, WHO announcing in 1979 the eradication of smallpox, and the discovery
of penicillin and streptomycin. Beyond public euphoria over accomplishments,
the scientific community’s incorrect view of the stagnant or slow-paced
evolutionary process towards benign microbes further eroded the perceived
threat of infectious diseases (Snowden, 2008). Feelings translated into action as
the 1969 International Health Regulations only required three reportable
diseases: yellow fever, plague and cholera (WHO, 1969).
As global conditions changed, researchers have expanded Omran’s
original model to fit and explain developments. One such expanded model,
described by Zakharov and Ivanova (2010), attempts to explain changes to
Russian epidemiology. Russia, having undergone a social upheaval, has seen a
drop in its population as a result of stagnate to decreasing birth rate with an
increased death rate. Seen in other developed nations with social upheaval, the
increased death rate is not only due to chronic diseases, but resurgence in
infectious diseases as a result of a failure in governmental public health
programs. These factors have lead to an overall decrease in the total population.
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The above model, while imperative to understanding overall global
epidemiological transitions, does not explain the emerging and re-emerging
pattern in infectious diseases observed within the last half century on a global
level.
In post-World War II, individuals who held the belief that infectious
diseases would drive themselves by means of natural selection towards a benign
existence were termed “eradicationists” (Snowden, 2008). The decrease
virulence of syphilis from the 16th century compared to the mid-twentieth century
was a pillar for the support of their theory (Snowden, 2008). Doubt in the validity
of the decreasing virulence theory began with novel disease discoveries during
the 1970s; however, the tipping point arrived in 1983 with the discovery of the
Human Immunodeficiency Virus (Shilts, 1988). Successive epidemics occurred
throughout the 1990’s. In 1991, an epidemic of cholera swept across Central
and South America (WHO, 2007). The US “four-corner” region was struck by a
mysterious severe pulmonary illness which rapidly killed 83 individuals in 1993.
Later identification of Hantavirus gave a name to the disease which had struck
apprehension into the United States population (Epstein, 1995). Finally, with an
epidemic of plague in India (1994) and the well publicized Ebola outbreak in
Zaire during 1995, a clear epidemiological transition was occurring (Snowden,
2008); but what was occurring and why was it taking place?
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Epidemiological Transition Theory: Model Expansion
Barrett and colleagues (1998), present a third epidemiological transition
the Age of “Emerging and Re-emerging Infectious Diseases”. Emerging
diseases, defined by Davis and Lederberg (2000) are “diseases of infectious
origin whose incidence in humans has increased within the past two decades or
threatens to increase in the near future.” The emerging and re-emerging
infectious disease theory is based on the following three defining criteria: 1)
numerous new diseases detected which are contributing to mortality, 2)
increasing prevalence and incidence of diseases previously thought to be
controlled, and 3) re-emerging diseases are developing anti-microbial resistance
faster than new drugs to combat them can be developed.
The first criteria is easily observable as 31 emerging infectious diseases
were identified from 1973-1995 (Lederberg, 1997). Currently, the United States
National Institute of Allergy and Infectious Diseases (NIAID) lists 16 emerging
and five re-emerging infectious diseases identified within the last two decades
(Table 1A, NIAID, 2010). Defending the second criteria is the estimate that more
people are infected with tuberculosis than at any time in human history (Hayward
& Coker, 2008). Microbial resistance was first discovered in 1917 during the
testing of the organic chemical Optochine (C21H28N2O2) in the treatment of
pneumococcal pneumonia (Moellering, 1995, as cited in Barrett et al., 1998).
Microbial resistance continues to be a major public health hazard seen in the
estimated 19,000 deaths in the US during 2005 caused by strains of
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Staphylococcus aureus resistant to commonly administered antibiotics (Klevens
et al., 2007).
As a result of highly publicized infectious disease outbreaks (e.g. ebola,
necrotizing fasciitis (e.g. Streptococcus pyogenes), human immunodeficiency
virus (HIV)) and food recalls as a result of contamination with Escherichia coli
O157:H7, popular opinion may point towards an overwhelming increase in the
incidence and prevalence of infectious diseases; however, is the infectious
disease apprehension we are experiencing today simply a result of increased
surveillance capabilities? Until 2008, no analytic study had been published which
undertook this question in a systematic manner. Jones (2008) published a study
in which he compiled data on infectious diseases and surveillance capabilities
from 1940 to 2004. Results of the study show that infectious diseases have been
emerging at a rate above expected increases due to improved surveillance
coverage. Furthermore, infectious disease emergence was shown to peak in the
1980’s, but emergence today still exceeds that in the 1940’s (Jones, 2008).
Decreased funding for infectious disease public health programs during
the 1960’s and 1970’s played a large role in the emergence and re-emergence of
infectious diseases, but many other factors have significantly contributed. Cohen
(2000) has presented a graphic representation of the risk factors which have
contributed to infectious disease emergence and re-emergence (Figure 2A).
These risk factors include changes to human behavior; demographics changes,
of which population increase and urbanization are significant contributors;
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technological changes; industry changes; environmental changes; travel, and
more specifically mass travel; decreases in public health infrastructure; and
microbial adaptation (Cohen, 2000).

Table 1A. NIAID Global Emerging and Re-emerging Infectious Diseases: 1990Present.
Emerging
Acanthamebiasis
Australian bat lyssavirus
Babesia, atypical
Bartonella henselae
Ehrlichiosis
Encephalitozoon cuniculi
Encephalitozoon hellem
Enterocytozoon bieneusi
Helicobacter pylori
Hendra or equine morbilli virus
Hepatitis C
Hepatitis E
Human herpesvirus 8
Human herpesvirus 6
Lyme borreliosis
Parvovirus B19

Re-Emerging
Enterovirus 71
Clostridium difficile
Mumps virus
Streptococcus, Group A
Staphylococcus aureus

While the risk factors to increased infectious disease outcomes have been
identified, the consequences on birth rates, death rates, and total population
have yet to fully manifest as the emerging and re-emerging epidemiological
transition is ongoing. Currently, public health efforts have been relatively
successful in reducing the impact of acute infectious disease pandemics (e.g.
SARS in 2003 and Influenza in 2009). However, a great disparity has arisen with
regard to chronic infectious disease pandemics, such as HIV and tuberculosis.
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These chronic infectious diseases, which have long latency and infectious
periods, have increasingly affected all countries, but middle- and low- income
countries have incurred the majority of the burden (Corbett, 2003). Ongoing
vaccination development research and other similar public health endeavors help
but do not fix the underlying causes of health disparity, being poverty, education,
dietary needs and access to affordable healthcare (Snowden, 2008). Even with
all the advances in health technology, Lederberg (1997) suggests that we are
currently more susceptible to pandemic and communicable diseases threats than
at any time in human history.

Figure 2A. “Changes in society, technology, environment and microorganisms
are leading to increases in host susceptibility and/or disease transmission and
the evolution of new or drug-resistant microorganisms” (Cohen, 2000).
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WHO is predicting that non-infectious diseases will be responsible for little
more than 5% of all global deaths by 2030 (WHO, 2008) (Figure 3A). When
international organizations and governments decide to distribute aid and
research funding the increasing prevalence on chronic diseases must be taken
into consideration. Controlling chronic diseases must be met with the same, if
not greater, monetary and cooperative effort seen in taking on infectious
diseases in post-World War II. In the same breath, infectious diseases must not
be forgotten, as history has already shown us their ability to emerge and reemerge if public health infectious disease programs are de-funded. Unlike most
chronic diseases, many infectious diseases have the potential to be eradicated
by-well designed vaccines. Vaccine development should continue to be at the
forefront of infectious disease funding. Understanding the biological pathway
behind infectious disease pathogenesis is imperative for vaccine and treatment
advancement. The effort to understand infectious disease pathogenesis must
not be limited to funding of laboratory endeavors. Sponsorship of field and
clinical epidemiology provides crucial evidence on the population effected.
Epidemiology has aided in the discovery that diseases are not caused by “bad
air”, that HIV is not a disease limited to homosexuals, and that Severe Acute
Respiratory Syndrome (SARS) is spread through direct or indirect transmission
(Hempel, 2007; Shilts, 1988; PubMed Health, 2009).
Epidemiological studies, whether through surveillance or well-designed
targeted studies, should not be thought of as a one-time undertaking to
169

comprehend an infectious disease as they have shown an uncanny ability to
mutate and spread to novel geographic regions (Lowy, 2010). To fully
understand a disease, epidemiological studies must encompass all potentially
effected individuals in regards to place, but also time. The following section
presents a historic review of dengue epidemiology.

Figure 3A. The shift towards noncommunicable diseases and accidents as
causes of death. (WHO, 2008) edited.
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Appendix B: Primary Study Population Descriptive Tables

Table 1B. Dengue Manifestations in Source Study Participants by 2009 WHO Dengue
Diagnostic Scheme from Hospital Ampang, 2010.
Without
NonWarning
Dengue
Signs
*
n %
n %
Manifestation
Total Study Participants 22 8.0 27 9.8
Abdominal Pain
12 54.6
1 3.7 ‡
Arthraglia/Myaglia
17 77.3 20 74.1
Diarrhea
7 31.8 11 40.7
Hepatosplenomegaly
5 22.7
2 7.4
Nausea/Vomiting
15 68.2 10 37.0
Postural Giddiness
6 27.3
9 33.3
Rash
1 4.6
3 11.1
Retro-orbital/Headache 10 45.5 16 59.3
Viral Hepatitis
3 13.6 16 59.3 ‡
Bleeding Tendency
#

(Any)

5 22.7

2

7.4

^

With
Warning
Signs
n
%
222 80.4
161 72.5 ¥
184 82.9
130 58.6
65 29.3
203 91.4 ‡¥
86 38.7
39 17.6
112 50.5
162 73.0 ‡
62

27.9

Severe
n %
5
1.8
2 40.0
3 60.0
2 40.0
3 60.0
5 100.0 ‡¥
2 40.0
4 80.0
2 40.0
2 40.0
3

60.0

Dengue
Total
n
254
164
207
143
70
218
97
46
130
180

%
92.0
64.6
81.5
56.3
27.6
85.8
38.2
18.1
51.2
70.9 ‡

67 26.4

^

Fisher's exact test (2-tails) with Bonferroni correction.
* Other: Ascites (n=2), Pleural Effusion (n=7), & Petechiae/Bruises (n=4)
#

Includes: epistaxis, gum provocative & spontaneous, hemetemesis, melena, menorrhagia,
retinal and subconjunctival.
'Non-Dengue' control with level of significance: † ≤0.05 ; ‡ ≤0.01
'Without Warning' control with level of significance: ¥ ≤0.05
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Table 2B. Blood Profile of Source Study Participants by 2009 WHO Dengue Diagnostic Scheme from Hospital Ampang, 2010.
Non-Dengue
Without Warning
With Warning
Severe
Total Dengue
Profile Component n
Avg. ± S.D.
n
Avg. ± S.D.
n
Avg. ± S.D.
n Avg. ± S.D.
Avg. ± S.D.
#

Hemoglobin
Febrile
Defervescence
Convalescence

13
20
16

13.1 ± 1.5
13.4 ± 1.8
13.0 ± 1.9

18
25
23

14.3 ± 1.4
13.7 ± 1.6
14.0 ± 1.4

154
219
201

13.9 ± 1.8
13.6 ± 1.8
13.7 ± 1.7

4
5
5

13.0 ± 2.3
13.8 ± 1.7
12.6 ± 1.9

13.9 ± 1.7
13.6 ± 1.8
13.7 ± 1.7

14
20
17

39.2 ± 4.1
40.0 ± 5.2
38.2 ± 5.1

15
26
22

43.3 ± 3.5 †
41.2 ± 5.9
42.0 ± 5.9

155
221
202

42.1 ± 4.9
41.0 ± 5.5
41.5 ± 4.7

4
5
5

39.4 ± 7.7
41.5 ± 5.6
38.8 ± 5.8

42.1 ± 4.8
41.0 ± 5.4
41.5 ± 4.9 †

14
20
17

107.9 ± 58.3
96.7 ± 44.0
198.2 ± 71.8

14
20
17

&

Hematocrit
Febrile
Defervescence
Convalescence

†

*

Platelet
Febrile
Defervescence
Convalescence

18 85.9 ± 52.9
26 70.1 ± 36.2
23 209.7 ± 118.7

155 77.1 ± 42.4 †
222 61.3 ± 43.2 ‡
202 228.6 ± 140.9

4 107.3 ± 8.4
5 82.8 ± 37.1
5 324.4 ± 191.2

78.7 ± 43.2
62.6 ± 42.4 ‡
228.8 ± 140.2

5.7 ± 3.1
5.4 ± 3.2
6.5 ± 2.2

18
26
22

3.6 ± 1.6
4.2 ± 2.1
6.3 ± 2.2

155
220
202

3.5 ± 1.9
5.0 ± 2.4
7.0 ± 5.4

‡

4
5
5

5.7 ± 3.3
6.7 ± 4.9
7.1 ± 2.8

3.6 ± 1.9
4.9 ± 2.4
6.9 ± 5.1

12
17
15

4.1 ± 2.3
3.7 ± 3.3
3.9 ± 1.7

12
22
22

1.5 ± 0.8
1.3 ± 0.8
2.5 ± 1.0

142
218
210

1.9 ± 1.4
1.7 ± 1.3
2.9 ± 1.7

‡
‡

4
5
5

4.4 ± 3.6
3.7 ± 4.3
3.2 ± 1.9

1.9 ± 1.5
1.7 ± 1.4
2.8 ± 1.6

12
17
15

1.5 ± 1.7
1.4 ± 0.5
2.5 ± 1.2

12
22
22

1.2 ± 0.7
1.8 ± 1.1
2.8 ± 0.9

142
218
210

1.0 ± 0.6
1.9 ± 1.0
2.7 ± 1.0

4
5
5

0.7 ± 0.7
1.5 ± 1.0
2.9 ± 1.1

1.0 ± 0.6
1.9 ± 1.0†
2.7 ± 1.0

11
17
12

0.6 ± 0.3
0.6 ± 0.3
0.7 ± 0.4

10
21
18

0.7 ± 0.5
1.1 ± 0.9
0.9 ± 0.9

125
199
182

0.6 ± 0.7
1.2 ± 0.9
0.9 ± 0.7

4
5
5

0.5 ± 0.1
0.9 ± 0.3
0.7 ± 0.4

0.6 ± 0.7
1.2 ± 0.9
0.9 ± 0.7

11
17
12

0.03 ± 0.07
0.06 ± 0.09
0.13 ± 0.11

10
21
18

0.03 ± 0.09
0.03 ± 0.08
0.12 ± 0.14

125
199
182

0.01 ± 0.06
0.05 ± 0.10
0.15 ± 0.17

4
5
5

<0.0 ± <0.0
0.02 ± 0.05
0.06 ± 0.09

0.01 ± 0.06
0.05 ± 0.09
0.14 ± 0.16

*

Total White Cell
Febrile
Defervescence
Convalescence
*

Neutrophil
Febrile
Defervescence
Convalescence

‡
†
†

†
†

*

Lymphocyte

Febrile
Defervescence
Convalescence
*

Monocyte
Febrile
Defervescence
Convalescence
*

Eosinophil
Febrile
Defervescence
Convalescence
*

Basophil
Febrile
11 <0.00 ± <0.00
10 <0.00 ± <0.00
125 0.01 ± 0.03
4 <0.00 ± <0.00
Defervescence
17 <0.00 ± <0.00
21 <0.00 ± <0.00
199 0.01 ± 0.03
5 <0.00 ± <0.00
Convalescence
12 <0.01 ± 0.03
18 0.01 ± 0.03
182 0.02 ± 0.04
5 0.02 ± 0.05
^ Independent student t-test with Bonferroni correction. 'Non-Dengue' control group.
Level of Significance: † ≤0.05; ‡ ≤0.01
*
&
#
(x10^9) ; % ; (g/dL)
Note: Significant associations were not detected between Without & With Warning groups.
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0.01 ± 0.03
0.01 ± 0.03
0.02 ± 0.04

‡

Table 3B. Renal Profile of Source Study Participants by 2009 WHO Dengue Diagnostic Scheme from Hospital
^
Ampang, 2010.
Non-Dengue
Without Warning
With Warning
Severe
Total Dengue
Profile Component n Avg. ± S.D.
n Avg. ± S.D.
n Avg. ± S.D.
n Avg. ± S.D.
Avg. ± S.D.
*

Urea
Febrile
11 5.3 ± 3.2
Defervescence 17 4.5 ± 3.7
Convalescence 14 4.1 ± 1.8

11
22
17

3.9 ± 1.7
2.5 ± 1.2
2.8 ± 1.1

132 3.2 ± 1.6 ‡
215 2.4 ± 1.0 ‡
173 2.5 ± 1.1 ‡

3
5
5

3.3 ± 0.8
2.9 ± 1.4
3.1 ± 1.4

132 136.2 ± 3.5
215 139.1 ± 2.9
172 139.8 ± 2.6

3 133.3 ± 4.5
5 138.0 ± 2.4
5 140.6 ± 2.1

3.2 ± 1.6
2.5 ± 1.1
2.5 ± 1.1 †

11
22
17

135.5 ± 3.9
140.4 ± 4.8
140.6 ± 2.6

11
22
17

3.5 ± 0.2
3.7 ± 0.4
3.8 ± 0.3

11
22
17

102.2 ± 4.6
107.2 ± 5.3
105.1 ± 4.2

132 101.6 ± 4.4
215 105.8 ± 4.0
173 104.3 ± 3.8

3 97.0 ± 6.1
5 102.6 ± 5.6
5 103.0 ± 1.2

101.6 ± 4.4
105.8 ± 4.2
104.3 ± 3.8

11
21
17

94.6 ± 27.0
66.6 ± 18.6
69.8 ± 21.8

132 74.1 ± 23.3 ¥
215 63.3 ± 17.1 ‡
173 62.1 ± 16.3 ‡

3 92.0 ± 22.6
5 75.8 ± 35.4
5 60.8 ± 33.0

76.0 ± 24.1
63.8 ± 17.7
62.7 ± 17.0

*

Sodium
Febrile
11 136.3 ± 7.3
Defervescence 17 138.4 ± 4.3
Convalescence 14 139.9 ± 2.6

136.1 ± 3.5
139.2 ± 3.1
139.9 ± 2.6

*

Potassium
Febrile
10 3.9 ± 0.4
Defervescence 17 3.7 ± 0.4
Convalescence 14 3.7 ± 0.4

† 132 3.6 ± 0.4
214 3.7 ± 0.5
173 4.0 ± 2.3

3
5
5

4.4 ± 1.0 †
3.7 ± 0.4
3.8 ± 0.4

3.6 ± 0.4
3.7 ± 0.5
4.0 ± 2.1

*

Chloride
Febrile
11 102.7 ± 7.0
Defervescence 17 105.6 ± 4.7
Convalescence 14 106.0 ± 4.2
&

Creatinine
Febrile
11 94.1 ± 49.7
Defervescence 17 84.7 ± 52.9
Convalescence 14 82.1 ± 29.0
^

Independent student t-test with Bonferroni correction.
† ≤0.05 level of significance with 'Non-Dengue' control group.
¥ ≤0.05 level of significance with 'Without Warning' control group.
*

&

mmol/L ; umol/L
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Table 4B. Liver Profile of Source Study Participants by 2009 WHO Dengue Diagnostic Scheme from Hospital Ampang,
^
2010.
Non-Dengue
Without Warning
With Warning
Severe
Total Dengue
Profile Component
n Avg. ± S.D.
n Avg. ± S.D.
n
Avg. ± S.D.
n Avg. ± S.D.
Avg. ± S.D.
*

Total Bilirubin
Febrile
Defervescence
Convalescence
&
Alkaline Phosphatase
Febrile
Defervescence
Convalescence

11 34.0 ± 52.9
15 14.0 ± 12.1
14 15.0 ± 11.8

11
22
21

10.6 ± 8.0
7.3 ± 3.8
8.6 ± 3.5

132
215
210

‡
‡
‡

3 12.7 ± 11.7
5 12.8 ± 8.3
5 11.8 ± 7.3

8.4 ± 5.4
8.6 ± 4.9
10.0 ± 5.5

11 71.7 ± 27.4
15 91.7 ± 82.9
14 92.8 ± 60.2

11
22
21

82.3 ± 70.5
56.9 ± 34.0
72.2 ± 55.2

131 66.8 ± 31.4
215 64.6 ± 35.3 †
210 73.9 ± 36.9

3 68.7 ± 13.8
5 56.2 ± 15.2
5 62.8 ± 16.0

68.0 ± 35.4
63.7 ± 34.9
73.6 ± 38.5

11 65.3 ± 7.9
15 59.9 ± 4.2
14 67.1 ± 9.9

11
22
21

66.1 ± 7.4
62.0 ± 4.8
72.7 ± 7.1

131
215
210

67.4 ± 8.3
61.9 ± 6.9
73.2 ± 8.7

†

3 73.7 ± 4.2
5 66.8 ± 9.1
5 74.0 ± 6.8

67.5 ± 8.2
62.0 ± 6.8
73.2 ± 8.5

11 34.6 ± 5.1
15 32.1 ± 5.0
14 35.9 ± 8.3

11
22
21

38.4 ± 4.5
34.2 ± 3.5
40.6 ± 3.5

131
215
210

37.9 ± 4.5
34.1 ± 3.9
40.5 ± 4.9

†

3 39.0 ± 1.0
5 35.4 ± 7.3
5 39.6 ± 6.1

38.0 ± 4.4
34.2 ± 4.0
40.5 ± 4.8

11 30.7 ± 5.8
15 27.9 ± 4.1
14 31.3 ± 4.8

11
22
21

27.7 ± 4.9
27.7 ± 4.8
32.0 ± 5.7

131
215
210

29.5 ± 6.3
27.7 ± 4.9
32.7 ± 6.4

3 34.7 ± 4.5
5 31.4 ± 4.2
5 34.4 ± 4.3

29.5 ± 6.2
27.8 ± 4.9
32.7 ± 6.3

11 53.6 ± 47.9
15 75.3 ± 77.4
14 51.9 ± 27.8

11
22
21

77.4 ± 47.7
95.0 ± 95.4
77.9 ± 55.9

131 90.6 ± 84.0
215 115.8 ± 112.7
210 90.5 ± 72.5

3 43.0 ± 9.0
5 67.2 ± 42.7
5 94.2 ± 96.9

88.6 ± 81.1
112.9 ± 110.4
89.5 ± 71.5

8.1 ± 4.9
8.7 ± 4.8
10.1 ± 5.6

#

Total Protein
Febrile
Defervescence
Convalescence
#

Albumin
Febrile
Defervescence
Convalescence
#

Globulin
Febrile
Defervescence
Convalescence
&

Alanine Aminotransferase
Febrile
Defervescence
Convalescence
^

Independent student t-test with Bonferroni correction. 'Non-Dengue' control group.
Level of Significance: † ≤0.05; ‡ ≤0.01
*

&

#

umol/L ; U/L ; (g/L)
Note: Significant associations were not detected between Without & With Warning groups.
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†

Table 5B. Vital Statistic Profile of Source Study Participants by 2009 WHO Dengue Diagnostic Scheme from Hospital
^
Ampang, 2010.
Non-Dengue
Without Warning
With Warning
Severe
Total Dengue
Profile Component
n Avg. ± S.D.
n Avg. ± S.D.
n Avg. ± S.D. n Avg. ± S.D.
Avg. ± S.D.
Temperature (˚C)
Febrile
15 38.9 ± 0.7
18 38.6 ± 0.8
148 38.7 ± 0.8
4 39.0 ± 0.9
38.7 ± 0.8
Defervescence
18 37.0 ± 0.3
22 37.1 ± 0.2
186 37.1 ± 0.3
2 36.7 ± 0.4
37.1 ± 0.3
Convalescence
4 37.0 ± 0.6
4
37.2 ± 0.3
7 36.9 ± 0.1
1
37
37.0 ± 0.3
#

Systolic Blood Pressure
Febrile
Defervescence
Convalescence

15 123.8 ± 30.2
18 124.4 ± 20.3
4 109.8 ± 11.6

18 122.4 ± 16.9
21 115.7 ± 13.2
5 109.0 ± 5.5

148 121.7 ± 15.2
173 118.2 ± 12.5
5 117.4 ± 19.2

4 99.0 ± 18.1
2 118.0 ± 25.5
0
-

121.5 ± 17.2
118.5 ± 13.5
112.2 ± 13.0

15 73.3 ± 15.7
18 75.9 ± 7.7
4 75.0 ± 7.0

18
20
5

73.9 ± 10.9
72.6 ± 11.8
72.0 ± 9.3

148 75.2 ± 12.0
173 75.8 ± 9.7
5 66.8 ± 5.1

4 60.0 ± 17.2
2 67.0 ± 9.9
0
-

74.6 ± 12.4
75.4 ± 9.8
71.0 ± 7.6

15 96.3 ± 19.6
0
4 75.5 ± 9.0

18
0
4

93.8 ± 17.6
80.8 ± 17.4

147 93.2 ± 16.4
0
5 79.6 ± 7.2

4 106.3 ± 9.1
0
0
-

93.8 ± 16.7
78.7 ± 10.9

#

Diastolic Blood Pressure
Febrile
Defervescence
Convalescence
*

Pulse Rate
Febrile
Defervescence
Convalescence
^
*

Independent student t-test with Bonferroni correction.
#

mmHg ; beats per minute
Note: Significant associations were not detected with control group as 'Non-Dengue' or 'Without Warning.'
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Appendix C: SAS® Code for Statistical Analysis

***********************************************************************
*********************
SAS Program for Benjamin Klekamp's thesis: 2011
Defended May 17th, 2011
Uses SAS dataset: Thesis_Final
***********************************************************************
*********************;
*Importing the datset;
libname perm "C:\Users\Desktop\Ben\Thesis\" ;
Data data1 ; Set perm.thesis_final ; run;
*Hemagglutination inhibition results - collaspsing into primary and
secondary infection
*Only outputs primary and secondary infections
*HemIn - is hemagglutination inhibition (exposure) variable (binary
(1&2)) ;
Data data2 ; Set data1 ;
if HI = 'p2' then HemIn = 2 ;
else if HI = '2' then HemIn = 2 ;
else if HI = '1' then HemIn = 1 ;
else if HI = 'p1' then HemIn = 1 ;
else HemIn = 0 ;
if HemIn ne 0 then output;
run;
*Some participants did not have a blood profile conducted during
defervescence phase of illness
*Absolute Monocyte Count (part of the blood profile) is the outcome
variable
*mono2 - was the variable representing absolute monocyte count during
defervescence
*Only those participants who have a recorded value for mono2 are
output;
Data Data3; Set Data2;
if mono2 ne . then output; run;
*Creating a variable to be used in the secondary aim analysis
*HEM_VL = absence (0) or presence (1) of hemorrhage and/or vascular
leakage;
Data Data4; Set Data3;
VL=0;
Hem=0;
*VL = vascular
leakage;
HEM_VL=0;
*HEM = hemorrhage;
if HCT1 ne . and HCT2 ne . then do; *HCT1 = febrile hematocrit;
HCTp = (HCT1 - HCT2)/HCT1*100;
*HCT2 = defervescence
hematocrit;
if HCTp ge 20 then VL = 1;
*HCTp = hematocrit percent
change;
if HCTp le -20 then VL = 1;
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if PE = 1 then VL = 1 ;
(1) of pleural effusion;
if ASC = 1 then VL = 1 ;
presence (1) of ascites;
if SBP2 lt 90 then VL = 1;
pressure at defervescence;
if ((SBP2-DBP2)) le 20 then VL = 1; *DBP2
defervescence;
end;
if
SGB
EPIX
MNG
HEMT
SCH
RH
MEL
then

= 1
= 1
= 1
= 1
= 1
= 1
= 1
Hem

or
or
or
or
or
or

*PE = absence (0) or presence
*ASC = absence (0) or
*SBP2 = systolic blood
= distolic blood pressure at

/*Spontaneous gum bleeding*/
/*Epistaxis*/
/*Menorrhagia*/
/*Hemetemesis*/
/*Subconjunctival haemorrhage*/
/*Retinal haemorrhage*/
/*melena*/

= 1 ;

if Hem = 1 or VL = 1 then HEM_VL = 1; run;
*Age of patient is calculated;
*Duration between first symptom and admission is calculated
(Tadmission);
*Duration of Hospitlization is calculated (Tdischarge);
*Classifying age into youth - adult, non-youth - elderly;
*Classifying distance between patient residence and Hospital Ampang by
12.5km;
*Combining manifestation variables for analysis ;
Data Data5; Set Data4;
AGE=(DATE2-DOB)/365.25; *Date2 = date of defervescence blood draw;
*DOB = Date of birth;
Tadmission=DOA - FEVD ; *DOA= Date of admission;
sysmptom;
Tdischarge=DOD - DOA ; *DOD= Date of Discharge;
if Age ge 15 and Age lt 25 then
else if Age ge 25 and Age lt 35
else if Age ge 35 and Age lt 45
else if Age ge 45 then Age1 = 4

*FEVD= Date of first

Age1 = 1;
then Age1 = 2;
then Age1 = 3;
;

if kilometers le 12.5 then KM = 0 ;
else km = 1;
if arth = 1 or mya = 1 then MYAR = 1 ; *arth= arthralgia; *mya=
myalgia;
else myar = 0;
if spleen = 1 or liver = 1 then HEPspl = 1 ; *spleen= Splenomegaly;
*liver= Hepatomegaly;
else hepspl = 0 ;
if nau = 1 or vom = 1 then nauvom = 1 ; *nau = nausea; *vom=vomitting;
else nauvom = 0;
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run;
*Creation of a final permenent dataset to work off;
Data perm.FINAL ; Set data5 ; run;
***********************************************************************
********;
*ANALYSIS OF THE DATASET;
***********************************************************************
********;
* Creating time to admission and time to discharge values;
proc means data= perm.final;
var Tadmission Tdischarge; run;
proc sort data=perm.final; by hemin; run;
proc means data= perm.final;
by hemin;
var Tadmission Tdischarge;
run;
proc sort data=perm.final; by hem_vl; run;
proc means data= perm.final;
by hem_vl;
var Tadmission Tdischarge;
run;
*Table 1 was copied from previous report;
*Creating values for Table 2;
proc freq data = perm.final;
table (sex race age1 km)*HemIn; run;
PRoc freq data= perm.final;
table (sex race age1 km)*Hem_vl ; run;
*Creating
proc freq
table (dm
proc freq
table (dm

Table 3;
data = perm.final;
HPT ckd ihd ccf)*HemIn; run;
data = perm.final;
HPT ckd ihd ccf)*hem_vl; run;

*Creating
proc freq
table (AP
run;
proc freq
table (AP

Table 4 ;
data = perm.final;
MYAR dia HEPspl nauvom pgid rash cereb hepa hem vl)*HemIn;
data = perm.final;
MYAR dia HEPspl nauvom pgid rash cereb hepa)*Hem_vl; run;

* Creating Table 5;
proc means data = perm.final;
var mono2 plt2 hct2 ; run;
proc sort data=perm.final; by hemin; run;
proc means data = perm.final;
by hemin;
var mono2 plt2 hct2 ; run;
proc sort data=perm.final; by hem_vl; run;
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proc means data = perm.final;
by hem_vl;
var mono2 plt2 hct2 ; run;
****Assessing Distance for confounding;
PRoc freq data=perm.final;
table Hemin*km / chisq;
run;
proc sort data= perm.final; by km; run;
proc means data=perm.final t prt mean std;
var mono2;
by km;
run;
PRoc freq data=perm.final;
table Hem_vl*km / chisq;
run;
*Creating Table 6 - linear regression;
proc reg data = perm.final ;
model mono2 = HemIN age sex race ;
output p=p r=r out=LinReg_base;
attrib _all_ label=' ';
title'Linear - Age continuous - without distance';
run; quit;
axis1 order=-2 to 3 by 1;
axis2 order=0.3 to 1.7 by 0.2;
title'Linear - Age continuous - without distance';
Proc gplot data=LinReg_base;
plot r*p / vaxis=axis1 haxis=axis2;
run; quit;
*Table 7 ;
proc reg data = perm.final ;
model mono2 = HemIN age sex race km ;
output p=p r=r out=LnReg_KM;
attrib _all_ label=' ';
title'Linear - Age continuous - with distance';
run; quit;
axis1 order=-2 to 3 by 1;
axis2 order=0.3 to 1.7 by 0.2;
title 'Linear - Age continuous - with distance';
Proc gplot data=LnReg_KM;
plot r*p / vaxis=axis1 haxis=axis2;
run; quit;
**************************************************;
*Table 8;
proc reg data = perm.final ;
model mono2 = HemIN age1 sex race ;
output p=p r=r out=LnReg_Age3;
attrib _all_ label=' ';
title'Linear - Age by 10 years - without distance';
run; quit;
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axis1 order=-2 to 3 by 1;
axis2 order=0.3 to 1.7 by 0.2;
title'Linear - Age by 10 years - without distance';
Proc gplot data=LnReg_Age3;
plot r*p / vaxis=axis1 haxis=axis2;
run; quit;
*Table 9;
proc reg data = perm.final ;
model mono2 = HemIN age1 sex race km ;
output p=p r=r out=LnReg_Age3km;
attrib _all_ label=' ';
title'Linear - Age by 10 years - with distance';
run; quit;
axis1 order=-2 to 3 by 1;
axis2 order=0.3 to 1.7 by 0.2;
title'Linear - Age by 10 years - with distance';
Proc gplot data=LnReg_Age3km;
plot r*p / vaxis=axis1 haxis=axis2;
run; quit;
****************************************************;
*Creating Table 10 - logistic regression;
proc logistic data = perm.final ;
class
sex race (descending) hemin / param =ref ref =last
;
model hem_VL (EVENT='1')= mono2 age sex race hemin
/ influence
lackfit;
output out=LogReg_base p=p reschi=PR;
attrib _all_ label=' ';
title'Logistic - Age continuous - without distance';
run;
title'Logistic - Age continuous - without distance';
Proc gplot data=LogReg_base;
plot pr*p ;
run; quit;
*Table 11;
proc logistic data = perm.final ;
class sex race (descending) hemin km (descending) / param =ref ref
=last
;
model hem_VL (EVENT='1')= mono2 age sex hemin race km / influence
lackfit ;
output out=LogReg_km p=p reschi=PR;
attrib _all_ label=' ';
title'Logistic - Age continuous - with distance';
run;
title'Logistic - Age continuous - with distance';
Proc gplot data=LogReg_km;
plot pr*p ;
run; quit;
*************************************************;
*Table 12;
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proc logistic data = perm.final ;
class age1 (descending) sex race (descending) hemin km (descending)
/ param =ref ref =last
;
model hem_VL (EVENT='1')= mono2 age1 sex hemin race / influence
lackfit ;
output out=LogReg_Age1 p=p reschi=PR;
attrib _all_ label=' ';
title'Logistic - Age by 10 years - without distance';
run;
title'Logistic - Age by 10 years - without distance';
Proc gplot data=LogReg_Age1;
plot pr*p ;
run; quit;
*Table 13;
proc logistic data = perm.final ;
class age1 (descending) sex race (descending) hemin km (descending)
/ param =ref ref =last
;
model hem_VL (EVENT='1')= mono2 age1 sex hemin race km / influence
lackfit ;
output out=LogReg_Age1km p=p reschi=PR;
attrib _all_ label=' ';
title'Logistic - Age by 10 years - with distance';
run;
title'Logistic - Age by 10 years - with distance';
Proc gplot data=LogReg_Age1km;
plot pr*p ;
run; quit;
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